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The microtubule associated protein tau (MAPT, commonly referred to as tau) is an intrinsically
disordered, highly soluble protein predominantly expressed in axons where it binds and stabilizes
microtubules. Under normal physiological conditions, soluble monomeric tau is released in the
extracellular space in the interstitial fluid (ISF) by neurons. Additionally it undergoes reversible
phosphorylation and other extensive modifications inside the cell under the action of a host of
enzymes. However in the disease process tau loses this solubility, detaches from microtubules and
ultimately migrates to the somatodendritic compartment of the neuron, where it ultimately forms
insoluble fibrillar aggregates known as tau tangles. The nature, timeframe, and inciting factors of
this transformation are active areas of research and as such, remain only partially understood.
xiii

In addition to its role in AD, tau is also implicated in several other neurodegenerative conditions
collectively referred to as tauopathies, all of which feature insoluble tau tangles. This list, which
is still evolving, includes conditions such as frontotemporal dementia (FTD), progressive
supranuclear palsy (PSP), corticobasal degeneration (CBD), chronic traumatic encephalopathy
(CTE), and argyrophilic grain disease (AGD). The prevailing hypothesis about the pathogenesis
of tauopathies is that following an initiating event, intracellular tau aggregates and eventually
spreads to other parts of the brain where it seeds previously normal tau, in a prion-like manner.
These seeding and spreading phenomena have been observed in numerous mouse models. The
nature of tau species involved in this spread, as well as the exact mechanism of trans-synaptic
spread are not well understood.
Tau’s involvement in neurodegeneration has made it an attractive therapeutic target. Passive
immunotherapy with monoclonal antibodies has shown promise and is being tested in clinical trials
in humans. Vaccination trials are also underway. In addition, other approaches such as antisense
oligonucleotides (ASOs) and small molecule inhibitors have been tested in animal models.
Here we have mainly focused on three distinct but related aspects in the “life of tau:”
1.

Developing methods to measure tau oligomers

2.

Determining clearance kinetics of extracellular tau from the CNS to the periphery

3.

Evaluating plasma tau as a potential biomarker for CNS tau pathology

Tau oligomers are thought to be an important intermediate step en route to the eventual
fibrillization of soluble monomeric tau. We developed a high-sensitivity assay on a single

xiv

molecule detection platform to detect tau oligomers, and demonstrated the effective of this assay
to detect tau oligomers in vitro, and in brain homogenates of transgenic mice.
Our work characterizing extracellular tau clearance is the first comprehensive work of its type and
strongly suggests that dural lymphatic system plays a key role in this process. Mice lacking these
lymph vessels retain more tau in the brain as well as show slowed clearance.
Lastly we asked whether plasma tau could serve as a reliable biomarker for soluble CNS tau and
give us an accurate snapshot of tau pathology. Administration of an anti-tau antibody resulted in
dose dependent increase in plasma tau in both humans and mice, most likely because of its role in
extending the half-life of plasma tau from 8 minutes to 3 hours. Furthermore plasma tau levels
correlated with soluble CNS tau levels (and therefore, inversely with tau pathology), making this
a potentially good strategy to monitor tau pathology load in mouse model of tauopathy and
potentially in humans.
The work done here represents an important step in characterizing the role of tau in normal
physiology and disease and will help guide future therapy as well as diagnostic approaches.

xv

Chapter 1 Introduction

1

1.1 Tau in Alzheimer disease
Alzheimer disease (AD) is the leading cause of dementia in the elderly and by some counts the
sixth leading cause of death in the United States. With increases in longevity, most experts estimate
that the number of people with AD will rise to 50 million over the next few decades(Holtzman,
Mandelkow, and Selkoe 2012). The two main neuropathological hallmarks of AD are extracellular
plaques of amyloid-beta (abeta) and largely intracellular neurofibrillary tangles (NFT) of tau
protein. The amyloid cascade hypothesis holds that the triggering event in AD pathogenesis is the
initial accumulation and aggregation of abeta into insoluble extracellular plaques. This is thought
to initiate a cascade of events that incite misfolding and aggregation of soluble tau into insoluble
neurofibrillary tangles, eventually leading to massive neuronal death (Musiek and Holtzman
2015). NFTs in AD are hyperphosphorylated as well as misfolded. Despite the apparent centrality
of abeta in governing the pathogenesis of AD, loss of cognitive function in patients is in fact
directly correlated to tangle load, and not plaque load. Because of its involvement in AD pathology,
tau has been the focus of intense research efforts designed to unravel its role in the pathogenesis
of AD and other forms of neurodegeneration. Tau tangles can be found in the brainstem and limbic
regions of healthy asymptomatic individuals(Braak and Del Tredici 2011). But in AD there are
extensive tangles in the neocortex in addition to the hippocampus(Braak and Braak 1991),
suggesting that the mere aggregation of tau may not be toxic and that it needs a trigger to become
toxic.
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1.2 Tau in other forms of neurodegeneration
In addition to its key role in AD pathology, tau has also been implicated in a host of other
neurodegenerative disorders. Collectively termed tauopathies, these disorders all feature
aggregated forms of tau in various neuronal cell types(Mandelkow and Mandelkow 2012a).
Primary tauopathies, where tau is thought to be driver of pathogenesis, include conditions like
corticobasal degeneration (CBD), progressive supranuclear palsy (PSP), argyrophilic grain disease
(AGD), Pick’s disease (PiD), primary age-related tauopathy (PART), and more recently chronic
traumatic encephalopathy (CTE). A subset of frontotemporal dementias (FTD) – a multifactorial
degenerative disease – has also been identified as being caused by mutations in tau and is included
in this category(Li and Götz 2017 Tau-based therapies in neurodegeneration: Opportunities and
challenges). Several other rare causative mutations have been identified as well. This is clearly an
evolving category and will keep getting updated as research continues. Secondary tauopathies are
disorders where tau pathology is co-existent, but not necessarily predominant. This category
obviously includes AD but also other parkisonisms such as lewy body dementia (DLB), and
Parkinson disease dementia (PDD), where the primary culprit is misfolded and aggregated forms
of alpha-synuclein protein. Table 1.1summarizes a list of tauopathies as well as the diverse forms
of tau aggregates seen in each (adapted from (Li and Götz 2017)).
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1.3 Structure and physiological function of tau
The microtubule associated protein tau (MAPT, commonly referred to as tau) is an intrinsically
disordered, highly soluble protein predominantly expressed in axons where it binds microtubules.
Some expression is seen in testes, muscle and periphery as well. Originally discovered in the late
1970s(Weingarten et al. 1975) its significance in disease was largely overlooked until a series of
studies in the 1980s showed that it was the core component of neurofibrillary tangles(Kosik,
Joachim, and Selkoe 1987, Luo et al. 2014). Further genetic and protein characterization localized
the MAPT locus to chromosome 17(Neve et al. 1986). It was soon discovered that alternative
splicing leads to six different isoforms, depending on the presence or absence of an extra repeat
domain (which includes the aggregation prone region of the protein) and an extra amino domain.
Thus the isoforms range from 0N3R to 2N4R(Goedert et al. 1989).

Tau has a myriad of binding partners apart from microtubules and it interacts with an army of
enzymes that modify it in practically every way possible. Tau can get phosphorylated,
glycosylated, sumoylated, acetylated, ubiquitination and nitration among many other
modifications(for detailed overview see Mandelkow & Mandelkow, 2012). In common with other
IDPs such as alpha-synuclein, tau is prone to oligomerization and fibrillization.

4

Under normal physiological conditions neurons have been shown to release soluble monomeric
tau in the interstitial fluid (ISF) (Yamada et al. 2011a)The precise mechanism of this release is not
yet clear and studies have suggested exosomes, and extracellular vesicles as potential pathways of
release (Yamada 2017). It appears that the release of tau in extracellular space can be modulated,
as increasing neuronal activity increases tau secretion(Karch, Jeng, and Goate 2012, Pooler et al.
2013, Yamada, Holth, Liao, Stewart, Mahan, Jiang, Cirrito, Patel, Hochgräfe, et al. 2014), and
inhibiting lysosomal function decreases it ((Mohamed et al. 2014). Additionally protein folding
chaperones can also regulate secretion of tau (Fontaine et al. 2016).

Surprisingly despite decades of work on tau, its precise function in the neuron is unknown. One of
the earliest known function attributed to tau was assembly and stabilization of microtubules
(Weingarten et al. 1975). It is thought to play a role in axonal trafficking by perhaps regulating
dynein and kinesin motors and by maintaining a concentration gradient (Dixit et al. 2008, Drewes,
Ebneth, and Mandelkow 1998 MARKs and microtubule dynamics, Ebneth et al. 1998
mitochondria, and endoplasmic reticulum: Implications for Alzheimer’s disease, Mandell and
Banker 1996, Trinczek, Ebneth, and Mandelkow 1999), although this is undermined by the
observation that ablation of tau does not seem to affect axonal transport (Yuan et al. 2008). So it
is likely that tau’s role might not be essential and other microtubule binding proteins in the neuron
could compensate in the absence of tau. This is supported by the fact that deletion of both tau and
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MAP1B, another microtubule binding protein, leads to impaired axonal elongation and
development and is lethal in vivo (Takei et al. 2000).

(Partial) list of tauopathies
Name

Primary

Inclusions

Progressive supranuclear palsy (PSP)

Neuronal +
Glial

Corticobasal degeneration (CBD)

Neuronal +
Glial

Pick disease

Largely
neuronal

Argyrophillic grain disease (AGD)

Neuronal +
Glial

Chronic traumatic encephalopathy
(CTE)

Neuronal +
Glial

Primary age related tauopathy (PART) Neuronal
Globular glial tauopathy (GGT)
Secondary Alzheimer disease (AD)

Glial
Neuronal

Table 1.1. A list of tauopathies and the diverse type of tau aggregates seen in each (adapted from
(Li and Götz 2017))
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It has also been proposed that tau plays a role in modulating various cell signaling pathways by
binding kinases such as Fyn and Src (Ittner et al. 2010, Sharma et al. 2007).
Any claim to the essential physiological nature of tau in the cell is undermined by the fact that
knockout of tau does not seem to have catastrophic consequences. Tau knockout mice do not seem
to suffer from any major behavioral or cognitive deficits, nor do they suffer from early mortality
(Dawson et al. 2001, Harada et al. 1994, Roberson et al. 2007 Reducing endogenous tau
ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model.). In fact
reduction of tau seems to have a neuroprotective effect. Tau knockout mice are less susceptible to
seizures (Holth et al. 2013), and a similar effect is seen when tau mRNA levels are reduced with
antisense oligonucleotide (ASO) treatment (DeVos et al. 2013b). The consequences of tau
reduction are even more evident when animal models of abeta pathology are used. Tau reduction
in APP overexpression mouse models improves behavioral deficits without affecting abeta levels
(Ittner et al. 2010, Roberson et al. 2007). A possible mechanism underlying this interplay between
tau and abeta might be the kinase Fyn (Ittner et al. 2010, Ittner and Götz 2011, Roberson et al.
2011 ).

1.4 Prion-like spread of tau pathology in neurodegeneration
In recent years a lot of attention has been devoted to the mechanisms underlying tau’s “villainous”
transformation from a highly soluble monomer to an insoluble fibril and how this might relate to
its disease-mediating properties. This transformation process itself still remains poorly understood
but moderate breakthroughs have been made in elucidating how tau might be wreaking
7

neuropathological havoc in the diseased brain. In the late 1980s and early 1990s, Braak and
colleagues noted that in the brains of patients with AD, NFTs exhibited a stereotypical pattern of
distribution, that was characteristic enough that they developed a six stage system of classifying
the stage of disease based on the location and extent of tangle load (Braak and Braak 1991, 1997,
Braak and Braak 1995). Stage I-II are when tangle pathology is limited to transentorhinal cortex,
stages III-IV see tangle pathology spread to hippocampus and stages V-VI see extensive tangle
pathology in the neocortex. Thus tau pathology appears to be “spreading” to different brain
regions.

Recently this theory has gained a lot more traction to the point where it has been developed into a
full-fledged model aimed at explaining pathogenesis of not just tauopathies but several other
protein aggregation disorders such as Parkinson disease (PD), amyotrophic lateral sclerosis (ALS)
and frontotemporal dementia (FTD) (Jucker and Walker 2013) (Figure 1.1).
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Figure 1.1. The prion hypothesis: a putative unifying mechanism underlying neurodegeneration.
Previously normal version of the implicated protein misfolds and aggregates following an
inciting event. This abnormal version then spreads to other parts of the brain where it can seed
and cause other normal forms of itself to misfold and aggregate. For each protein (and its
corresponding disease) the initial pathology and its subsequent spread to other brain regions
follows a stereotypical pattern that can help stage and characterize the disease better. Figure
adapted from (Jucker and Walker 2013).

In the context of tau the first study demonstrating the possible cellular internalization and
propagation of pathogenic seeds was published in 2009 (Frost, Jacks, and Diamond 2009). A
9

number of in vitro studies have subsequently demonstrated this phenomenon (for instance
(Kfoury et al. 2012, Takeda et al. 2015, Wegmann et al. 2016, Wu et al. 2013).
Injection of brain lysate from a transgenic mouse carrying the human P301S mutation into a WT
mouse carrying a WT human tau transgene resulted in local seeding and uptake at the site of
injection and subsequent spreading to distant brain regions (Clavaguera et al. 2009). In the years
since many studies using a variety of inoculates have confirmed this finding. In addition to brain
lysates from transgenic mice (Ahmed et al. 2014, Clavaguera et al. 2014), cell lysates (Sanders et
al. 2014), synthetic recombinant tau fibrils (Iba et al. 2013, Peeraer et al. 2015) and tau extracts
purified from human brains (Boluda et al. 2014, Clavaguera et al. 2013, Guo et al. 2016, He et al.
2018, Lasagna-Reeves, Castillo-Carranza, Sengupta, Guerrero-Munoz, et al. 2012) have also
been shown to robustly induce uptake, seeding and spreading in the brain.
Tau seeds can be taken up by the cell via heparan sulfate proteoglycans (HSPGs) (Holmes et al.
2013). The stability of the initial seeds through generations of passaging and the variable seeding
strengths of different types of inoculates seems to suggest that there are various proteopathic tau
“strains” (Sanders et al. 2014, Sanders et al. 2016). Neuronal activity is known to regulate
release of tau in the ISF (Yamada, Holth, Liao, Stewart, Mahan, Jiang, Cirrito, Patel, Hochgräfe,
et al. 2014) and also the prion-like spread of tau pathology (Wu et al. 2016). The fact that
intraperitoneal injections are enough to trigger seeding and spreading (Clavaguera et al. 2014)
indicates that the pathogenic seeds might only need to be introduced in very small amounts in the
brain to initiate the prion-like cascade. Although bulk of the research done so far strongly
10

suggests that the injected seeds are not tau monomers one cell culture study reported that tau
monomer was sufficient in inducing seeding (Michel et al. 2014). Similar injection studies have
been conducted with alpha-synuclein to show that this mechanism might be shared among
several neurogenerative conditions (see (Jucker and Walker 2013) for a discussion of other
protein aggregation disorders).
In the midst of all the injection studies, a pair of breakthrough studies demonstrating in vivo
trans-synaptic spread of tau in an endogenous manner was published in 2012. By restricting
expression of human tau to the entorhinal cortex using an inducible tet-off system authors were
able to track its movement in the brain. They found that several months following its expression
tau was found to spread from entorhinal cortex to the dentate gyrus (de Calignon et al. 2012, Liu
et al. 2012).
In humans indirect evidence for this spreading phenomenon outside of bona fide prion diseases is
a study showing that a small segment of children inadvertently given growth hormone extracts
from diseased pituitary glands developed CJD and abeta aggregates and subsequent amyloid
plaque pathology via seeding and spreading as they aged (Jaunmuktane et al. 2015) and another
study showing possible transmission of cerebral amyloid angiopathy due to neurosurgery
(Jaunmuktane et al. 2018).
The development of a FRET biosenser-based seeding assay (Holmes et al. 2014, Kfoury et al.
2012) has made it possible to assess seeding activity of a variety of samples such as mouse and
human brain lysates, cell lysates, synthetic fibrils and microdialysates among others. Tau
11

extracted from various human brain regions has significant seeding activity, which can be
detected in the presence of scant or even prior to the formation of NFT pathology (DeVos et al.,
2018; Furman et al., 2017).

1.5 Role of tau oligomers in tau-mediated neurodegeneration
Tau oligomers represent an intermediate step in the fibrillization process of soluble monomeric
tau. Much attention has been lavished upon them on their putative role in tau-mediated
neurodegeneration. Chapter 2 covers tau oligomers in extensive detail but in brief: emerging
evidence suggests that tau oligomers do represent a distinct step in the transformation of tau and
are likely involved in some toxicity in neurodegeneration. Since the nature of tau species
mediating prion-like spread is not known tau oligomers have emerged as the leading culprits
driving this disease process. There is some evidence to back this claim but this area is still
largely unexplored.

1.6 Therapeutic strategies against tau
Tau makes an obviously attractive therapeutic target on account of its key role in several
neurodegenerative conditions. Several approaches have been tried: active immunization, passive
immunization, antisense oligonucleotides and other small molecules (Gallardo and Holtzman
2017, Li and Götz 2017). Active immunization against P301L mutant tau has been shown to
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ameliorate cognitive deficits and reduce pathology (Asuni et al. 2007, Bi et al. 2011,
Boutajangout, Quartermain, and Sigurdsson 2010). There are two vaccination trials ongoing in
humans (Li and Götz 2017)
Several studies have demonstrated efficacy of passive immunization by administering antibodies
against various forms of tau. Antibodies against various phosphorylation epitopes can reduce tau
pathology (Collin et al. 2014, Gu, Congdon, and Sigurdsson 2013) in mouse models of
tauopathy. Additionally p-tau antibodies can also help block TBI (Kondo et al. 2015). Targeting
abnormally folded tau with the antibody MC-1 was also successful at reducing pathology (Chai
et al. 2011a). Work done in our lab has shown that antibodies that effectively block seeding in
vitro are also potent at markedly reducing tau pathology in vivo and improving brain atrophy
(Yanamandra et al. 2013b, Yanamandra et al. 2015). In line with these encouraging results,
major clinical trials using monoclonal tau antibodies are in Phase II currently.

Recently antisense oligonucleotides (ASOs) have emerged as attractive therapeutic candidates.
By targeting mRNA sequence of a protein, ASOs can reduce protein expression or modify its
splicing pattern (Schoch and Miller 2017). Administration of ASO to the P301S mouse model of
tauopathy resulted in reduction of hyperphosphorylated tau pathology and improvement in
survival and brain atrophy(DeVos et al. 2017). Additionally ASOs can reduce hyperexcitability
and protect against seizures by their inhibitory action on tau(DeVos et al. 2013a).
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1.7 Scope of this work
The work presented here aims to shed light on three different aspects of tau – a day in the life of
tau.
Chapter 2 discusses the structure and formation of tau oligomers, and their role in potentially
mediating neurodegeneration and toxicity. We sought to develop a high-sensitivity assay to
reliably measure oligomers and explored whether in vivo microdialysis could help characterize
these species in the interstitial fluid.
Chapter 3 is devoted to the study of tau clearance, a process that is only vaguely understood. Our
goal was to characterize this fundamental process and focus on the possible role of dural
lymphatics.
Chapter 4 looks at the possibility of using plasma tau as a reliable biomarker for soluble CNS
tau. This work has obvious theranostic implications.
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Chapter 2 Development of a highly sensitive tau
oligomer specific assay for in vitro and in vivo
characterization

This chapter includes work done in collaboration with the laboratory of Marc Diamond (then at
Washington University, now at University of Texas, Southwestern) and Janssen pharmaceuticals.
Significant contributions were made by Floy Stewart and Hilda Mirbaha.
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2.1 Introduction
Very few subjects are as contentious, fuzzy and inscrutable as tau oligomers. That tau undergoes
oligomerization en route to its eventual fibrilization and aggregation is widely accepted to be
true. The details about this process – kinetics, structure and especially, significance and
relevance – are a matter of great discussion. Even the term ‘tau oligomer’ itself is confusing,
since there is no consensus on what its definition. While most studies to call any intermediate
soluble multimeric tau species ‘oligomers’, others have preferred to use a stricter size-based
cutoff. To add to the confusion, terms like protofibrils and granular filaments (Maeda et al. 2006,
Maeda et al. 2007) are also often used to describe pre-fibrillar tau. Regardless of semantic the
chaos surrounding nomenclature there is consensus that understanding the oligomerization (and
subsequent fibrillization) of soluble monomeric tau is important for understanding its role in
mediating neurodegeneration (Gerson and Kayed 2013 Formation and propagation of tau
oligomeric seeds).

2.1.1 Structure and formation of tau oligomers
Despite being soluble even at high concentrations tau is quick to form higher order species such
as dimers and trimers (Sahara et al. 2007) especially when a nidus such as heparin or arachidonic
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acid is present (Lasagna-Reeves, Castillo-Carranza, Sengupta, Sarmiento, et al. 2012
Identification of oligomers at early stages of tau aggregation in Alzheimer’s disease). Crossseeding by abeta and alpha-synuclein can also promote oligomerization (Lasagna-Reeves et al.
2010). These oligomeric intermediate species are often hyperphosphorylated and may have other
modifications (Sahara et al. 2013).

2.1.2 Tau oligomers in neurodegeneration
Tau oligomer researchers are big proponents of the theory that oligomers, and not NFTs, are
more potent and the real toxic species in tau-mediated neurodegeneration (Gerson and Kayed
2013). This is because NFT and filament pathology do not correlate well with neuronal cell death
in patients and in various mouse models (Andorfer, Kress, Espinoza, De Silva, et al. 2003, Spires
et al. 2006, Yoshiyama et al. 2007b). Studies in cell cultures and in inducible transgenic mouse
models of tauopathy show that injection of tau oligomers can cause synaptic and mitochondrial
dysfunction (Castillo-Carranza, Gerson, et al. 2014) by binding synaptic vesicle proteins and
inhibit long-term potentiation (LTP) and memory formation in the hippocampus (LasagnaReeves, Castillo-Carranza, Sengupta, Guerrero-Munoz, et al. 2012, Puzzo et al. 2017).
Furthermore suppression of soluble tau expression leads to improvement in mitochondrial
dysfunction (Kopeikina et al. 2011).
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More evidence implicating tau oligomers in disease process comes in the form of
neuropathological studies in humans and mouse models. Oligomers have been isolated from
post-mortem brains of AD (Lasagna-Reeves, Castillo-Carranza, Sengupta, Sarmiento, et al.
2012, Maeda et al. 2006) patients where they correlate with Braak stage and from CSF (Sengupta
et al. 2017) where they are elevated in AD patients compared to non-demented controls. They
have also been isolated from PSP brains where they are present in globose inclusions (Gerson et
al. 2014). Considering the role of inflammation in mediating neurodegeneration it is notable that
oligomers were found to associate with astrocytes and microglia in the retina and brains of
transgenic mouse model of tauopathy and post-mortem brains of FTLD and AD patients (Nilson
et al. 2017). Cerebrovascular deposition of oligomers was also found in tauopathies, PD,
alongside abeta aggregates in a mouse model (Castillo-Carranza et al. 2017) and in a rat model
of blast-induced TBI (Gerson et al. 2016)
The lack of a known culprit for mediating prion-like spread of tau pathology has made tau
oligomers prime suspects for this role. Cell culture systems have demonstrated uptake and
propagation of oligomeric and high-molecular weight tau species (Takeda et al. 2015, Wegmann
et al. 2016, Wu et al. 2013). Tau oligomers derived from AD brains with an oligomer specific
antibody have been shown to induce local seeding and subsequent spreading to distant regions
when injected in the brain of WT mice. These mice also exhibit behavioral deficits (LasagnaReeves, Castillo-Carranza, Sengupta, Guerrero-Munoz, et al. 2012). Similarly intracerebral
injection of oligomers derived from rat brains of a TBI model causes cognitive deficits in mice
overexpressing WT human tau(Gerson et al. 2016).
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2.1.3 Therapeutic strategies against tau oligomers
Therapeutic strategies against tau oligomers have mainly consisted of passive immunotherapy.
Treatment with an oligomer specific antibody in a mouse model of tauopathy reduced soluble tau
oligomer levels, improved behavior and reduced tau pathology (Castillo-Carranza, Sengupta, et
al. 2014b) thus suggesting that focusing on oligomers in addition to aggregates can yield good
results.
It is clear that proper characterization of tau oligomers in vivo can yield valuable insight into the
role of tau in pathogenesis of tauopathies.

2.2 Experimental outline
We sought to develop sensitive, robust and reproducible methods to collect and quantify tau
oligomers from various physiological compartments such as interstitial fluid (ISF). We addressed
two interlinked questions as part of this project:
1) Do tau oligomers exist in vivo? And
2) If so can we develop methods to collect and quantify them?
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One recent study described collection and analysis of high molecular weight soluble tau species
from mouse ISF using HPLC. These tau species were able to propagate in a cell culture
propagation system(Takeda et al. 2015). The isolation of these species depends on size-exclusion
columns and the measurement was carried out with a tau monomer ELISA, meaning there is still
a need for a true quantative oligomer specific assay.

2.3 Results
Here we report the development of tau oligomer specific sandwich ELISAs (using the same
capture and detection antibody). Using these ELISAs we measured tau oligomers in lysates from
various brain regions from aged P301S tau transgenic mice.
Further we demonstrate that microdialysis is a viable method for assessing tau oligomers. Our
results from various in vitro experiments show ~1% recovery of full length tau fibrils with a 1
million Da probe and a ~3% recovery when using purified tau oligomers of different sizes.
Recovery of oligomers was confirmed by direct fluorescence reading and by the FRET based tau
seeding assay.
Since putative tau oligomers are likely present in very small amounts in physiological
compartments like ISF or CSF, it is important to develop high-sensitivity assays to aid in their
detection. To this end we describe preliminary results regarding the successful translation of our
oligomer-specific ELISA to the Simoa HD1 Analyzer, a high-sensitivity single-molecule
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detection system. We also describe results from our initial attempts to measure tau oligomers by
in vivo microdialysis in P301S tau transgenic animals.

2.3.1 Successful collection of repeat domain (RD) tau oligomers by
microdialysis
Microdialysis is a versatile technique that allows access to analytes in the ISF of a living, awake,
freely moving animal and has proven valuable especially in neurodegeneration by enabling realtime monitoring of abeta (Cirrito et al. 2003b, Cirrito et al. 2005, Kang et al. 2009) and tau
(Yamada et al., 2011). Previous work in our lab using in vivo microdialysis in P301S tau
transgenic animals showed that soluble tau monomers are released physiologically in the ISF in
an activity dependent manner and soluble tau decreases as mice age and pathology increases
(Yamada et al. 2011a In Vivo Microdialysis Reveals Age-Dependent Decrease of Brain
Interstitial Fluid Tau Levels in P301S Human Tau Transgenic Mice, Yamada, Holth, Liao,
Stewart, Mahan, Jiang, Cirrito, Patel, Hochgrafe, et al. 2014 Neuronal activity regulates
extracellular tau in vivo). Before using microdialysis to attempt to collect putative tau oligomers
from mice, we tested the ability of microdialysis to tau oligomers in vitro. Figure 2.1 shows the
schematic for in vitro microdialysis.
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Figure 2.1. In vitro microdialysis for tau oligomers.
(adapted and modified from Wikimedia.org)
Microdialysis probe with a 1 million Dalton cutoff size was inserted in a solution of tau fibrils of
known concentration (1-2 ug/ml). As a good first step this was performed by using tau fibrils
made of the aggregation-prone repeat domain (RD) of tau. To measure any oligomers that may
have been collected by this benchtop in vitro microdialysis setup, we developed a RD tau
oligomer specific ELISA using the same capture and detection antibody, HJ 9.3. The epitope for
this antibody lies in RD of tau, making it an ideal candidate for a sensitive ELISA. Microdialysis
was performed with different flow rates to extrapolate and ultimately calculate a hypothetical
‘zero flow’ recovery concentration. Results are shown in Figure 2.2 Recovery for monomeric tau
under similar conditions is ~30% but recovery for RD fibrils was substantially higher than that,
at ~65%.
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Figure 2.2. In vitro microdialysis for RD tau oligomers.
This proof of concept experiment demonstrates about 65% recovery rate for RD tau oligomers by
in vitro tau microdialysis.

2.3.2 Successful collection of full-length (FL) tau oligomers by microdialysis
Next we attempted to measure full-length (FL) tau oligomers using microdialysis. In vitro
microdialysis for these oligomers was performed similar to RD tau oligomer microdialysis. After
a thorough screen of a panel of anti-tau antibodies, two viable candidates (HJ 8.7 and HJ 8.2)
were chosen for further optimization and characterization. As shown in Figure 2.3 the sensitivity
of these assays is ~1 ng/ml based on a standard curve generated using FL tau fibrils. Since HJ 8.7
is a n-terminal antibody and HJ 8.2 is a c-terminal antibody, having two separate assays targeting
two distinct regions of tau could be useful in generating a more complete profile of all the
different tau species potentially present in ISF or CSF.
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Figure 2.3. Representative standard curves from two tau oligomer-specific ELISAs.
Two separate oligomer-specific ELISAs (one directed at an n-terminal epitope and another at a
c-terminal epitope) were used to confirm successful collection of full-length (FL) tau oligomers
from in vitro microdialysis.

After successful recovery of FL tau oligomers and measurement by two separate oligomerspecific ELISAs we used HJ 8.7, the n-terminal antibody, for further in vitro microdialysis
experiments with FL tau oligomers as well as brain lysates from aged P301S tau transgenic mice.
Table 2.1 summarizes concentrations of oligomers as measured by the HJ 8.7/8.7b ELISA from
various in vitro experiments.

Experiment

Initial (ng/ml)

Recovered (ng/ml)

%recovery

IVMD 1

2000

4.86

0.24

IVMD 2

2000

10.02

0.50

IVMD 3

1000

1.41

0.14

IVMD 4

1000

3.14

0.31
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RAB 1

5036.8

60.75

1.21

RAB 2

7887.2

47.41

0.60

Table 2.1. Recovery of FL tau oligomers as measured by HJ 8.7/8.7b ELISA.
Series of in vitro microdialysis experiments with FL tau oligomers and brain lysates from aged
P301S tau transgenic mice. (IVMD=In vitro microdialysis; RAB=Brain lysates from 9mo male
P301S tau transgenic mice in reassembly buffer (soluble fraction)).

Fluorescently labeled purified FL tau oligomers were obtained from the Diamond lab. In addition
to measuring their concentration by ELISA, we also confirmed collection of oligomers by direct
fluorescence. These results are summarized in Table 2.2 and Table 2.3.

Purified oligomers

Initial (nM)

Recovered (nM)

%recovery

n=2

20.92

0.47

2.27

n=3

11.22

0.38

3.40

n=10

3.81

0.13

3.35

Table 2.2 Recovery of purified tau oligomers as measured by HJ 8.7/8.7b ELISA.
In vitro microdialysis was performed on fluorescent FL tau oligomers. Recovered amount
calculated after mass correction.
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Based on results from Tables 2.1 and 2.2, it appears that recovery for purified oligomers is more
efficient than for just fibrils. Table 2.3 confirms recovery of purified oligomers by fluorescence
reading.

Purified oligomers

Initial fluorescence

Recovered fluorescence

%recovery

n=2

2688

337

12.54

n=3

3514

603

17.16

n=10

2004

291

14.52

Table 2.3. Recovery of purified tau fibrils as measured by direct fluorescence reading.
Amount of fluorescent fibrils recovered by in vitro microdialysis were also measured using a
spectrophotometer.

Together the results from these in vitro experiments are highly encouraging, because they
confirm that microdialysis is a viable technique for assessment and measurement of tau
oligomers.

2.3.3 Measurement of tau oligomers from cortex, brainstem and hippocampus
of P301S mice
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As a next step we tested both assays using biological samples. Serial extraction was performed
on cortices of wild-type and 9 mo P301S animals. The RAB fraction contains largely soluble
monomeric tau and the RIPA fraction contains insoluble tau in addition to some soluble tau as
well. We took these RAB and RIPA fractions and tested them using both the HJ 8.7/8.7b and the
HJ 8.2/8.2b assays.
As shown in Figure 2.4, concentration of tau oligomers is 3-7x higher in RAB fraction than the
RIPA fraction, as measured by both assays.
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Figure 2.4. Measurement of tau oligomers in brain lysate fractions of the cortex in aged P301S
mice.
Both the n-terminal and the c-terminal based oligomer assays are effective at quantifying tau
oligomers from brain lysates. (Values are in ng/mg of protein present in the wet weight of tissue
extracted. RAB represents salt-soluble fraction; RIPA is detergent soluble fraction)

Further we measured oligomers from hippocampus and brainstem of 8.5 old male P301S mice
using HJ 8.7/8.7b assay. As seen with cortex, majority of tau oligomers in the hippocampus and
brainstem are collected in the soluble RAB fraction.

Tau oligomers in brainstem measured by HJ 8.7/8.7b
300

Conc (ng/mg)

250
200
150

100
50
0
RAB WT

RAB TG 1 RAB TG 2 RAB TG 3 RAB TG 4 RIPA WT RIPA TG 1 RIPA TG 2 RIPA TG 3 RIPA TG 4

Samples
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Tau oligomers in hippocampus measured by HJ 8.7/8.7b
350

Conc (ng/mg)

300
250

200
150
100
50
0

RAB WT

RAB TG 1 RAB TG 2 RAB TG 3 RAB TG 4 RIPA WT RIPA TG 1 RIPA TG 2 RIPA TG 3 RIPA TG 4

Samples

Figure 2.5. Tau oligomers in brainstem and hippocampus of aged P301S mice.

2.3.4 Towards a high-sensitivity assay: optimization on the Simoa analyzer
If tau oligomers are present in ISF, their concentration is likely very low. Thus we need to have
reliable assays with high sensitivity if we aim to measure their concentration. Our currently
oligomer-specific ELISAs (HJ 8.7/8.7b and HJ 8.2/8.2b) have a lower limit of detection of ~1
ng/ml. A 20-80x increase in sensitivity of these assays would enable us to detect putative
oligomers with much better sensitivity. One such high sensitivity platform is the Simoa analyzer,
developed by Quanterix Corp. First described in 2010 (Rissin et al. 2010b), the Simoa uses
femtoliter microwells just large enough to trap a single bead coated capture antibody. Antigen
concentration is titrated enough to get into a range where Poisson statistics dictate that each
positive well is a single-molecule detection event (Figure 2.6). Recently this platform was used
to calculate tau concentration in the plasma of Swedish hockey players before and after
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concussion. The limit of detection was ~20 fg/ml, an astonishing 1000x increase in sensitivity for
monomeric tau.

Beads:protein maintained at ~10:1
At this ratio, Poisson statistics dictate that beads either
have either one active immunocomplex (i.e.
antigen-detector-SBG) or none
In this reaction volume fluorescence builds up quickly
and minimal diffusion of fluorescence occurs,
leading to single molecule detection

Figure 2.6. Working principle of the Simoa
(adapted from ((Rissin et al. 2010b);Simoa white paper)

To see if we can translate our oligomer-specific ELISA to this platform, we worked with
Quanterix scientists for a week to optimize our assay on the Simoa. We were able to achieve
~100x increase in sensitivity in our HJ 8.7/8.7b ELISA after preliminary work. Based on a
standard curve generated using FL WT tau fibrils (just as in our ELISA), our LOD was ~30
pg/ml. This is shown in Figure 2.7.
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HJ 8.7/8.7b standard curve on Simoa

Conc

Mean

SD

%CV

(pg/ml)

AEB

AEB

AEB

2.5

AEB

2.0
1.5

0

0.0153 0.0004

2.69

13.7

0.0198 0.0008

3.84

41.2

0.0259 0.0008

2.97

123.5

0.0478 0.0019

3.87

370.4

0.1015 0.0008

0.76

1111.1

0.2608 0.0133

5.1

3333.3

0.7492 0.0783

10.4

10000

2.2409 0.2324

10.3

1.0
0.5
0.0
0

2000

4000

6000

Conc (pg/ml)

8000

10000

12000

Figure 2.7. Standard curve demonstrating optimization of the
HJ 8.7/8.7b ELISA on the Simoa.
Using the same antibody as the plate-based ELISA we created
a new oligomer assay for the Simoa platform with a LOD ~30
pg/ml, about 100x more sensitive than our conventional
assay. (AEB=avg enzyme per bead, analogous to OD value in
an ELISA).
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After the successful generation of a standard curve, we measured tau oligomers in cortex from 9
month old male P301S mice using the Simoa HD analyzer (Figure 2.8). Although the trend of
higher concentration in RAB fraction still holds, the values are ~10x higher than what was
measured by the conventional ELISA. Further optimization is needed in this case.

Conc (ng/mg)

Oligomer measurement using HJ 8.7/8.7b Simoa
3000
2000
1000
0
RAB RAB RAB RAB RAB RAB RAB RAB RAB RIPA RIPA RIPA RIPA RIPA RIPA RIPA RIPA RIPA
WT TG1 TG2 TG3 TG4 TG5 TG6 TG7 TG8 WT TG1 TG2 TG3 TG4 TG5 TG6 TG7 TG8
Samples

Figure 2.8. Tau oligomers from aged P301S brain lysates as measured by the Simoa

2.3.5 Attempts to measure tau oligomers in vivo by microdialysis
After the initial success of translating the HJ 8.7/8.7b assay to the Simoa, we attempted to
measure oligomers in ISF by in vivo microdialysis. For this purpose we performed in vivo
microdialysis with a 1 megadalton probe on both young (3 mo) and old (9 mo) mice. ISF was
collected over 48 hours and divided into two pools for analysis. Each fraction represents 90
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minutes of collection (~45 ul of ISF at the slower flow rate we used). Samples were loaded at
three different dilutions. Table 2.4 shows the results from this experiment, which strongly
suggests a slight increase in oligomer specific signal in older mice compared to the younger
mice.

Standards

Avg AEB

0

0.070455

10

0.082665

30

0.100395

100

0.159579

300

0.310008

1000

0.704024

3000

2.770925

10000

7.415564

Table 2.4. Slight increase in oligomer specific signal in aged
P301s animals (particular animal #152)

In order to establish that we were indeed detecting faint signal from tau oligomers from ISF we
decided to treat P301S animals with the seizure inducing cholinergic pilocarpine. Previous work
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from the lab showed that causing widespread seizures and cell death with pilocarpine leads to a
huge increase in tau in ISF (see Figure 2.9). Based on this we expected that injecting older
P301S mice with pilocarpine would cause a corresponding increase in signal as measured by the
HJ 8.7 oligomer assay.

Figure 2.9. 10-15 fold increase in tau concentration in ISF following treatment with the cholinergic
pilocarpine (arrow)
(adapted from (Yamada, Holth, Liao, Stewart, Mahan, Jiang, Cirrito, Patel, Hochgrafe, et al.
2014))

Baseline ISF was collected from 7 mo P301S females. Pilocarpine was given at 22 hours to
induce seizures and cell death. Seizures were terminated 10 minutes post-injection and ISF was
collected subsequently for 24 hours. To obtain some temporal resolution ISF fractions were
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divided into three separate pools (baseline, post-pilocarpine 1, post-pilocarpine 2). Table 2.5
shows results from this experiment. Although the signal was above background there was no
noticeable increase in oligomeric tau post-seizure induction in any of the mice.

Table 2.5. No increase in oligomeric tau post pilocarpine treatment in older P301S animals

The levels of tau in ISF rise significantly in the first few fractions after probe placement due to
injury. Thinking that this would result in an increase in tau oligomers as well, we measured the
first few fractions using the Simoa. Results are depicted in Table 2.6 and they show a modest
increase in two animals.
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Mouse

Mean AEB

SD

Concentration

Calculated

(pg/ml)

conc (pg/ml)

1

0.0461

0.00072

12.6108

63.0541

2

0.0525

0.00283

32.0126

160.0628

3

0.0503

0.00815

25.5013

127.5065

4

0.0464

0.00276

13.3527

66.7634

Table 2.6. Slight increase in oligomers immediately following probe placement.
This increase likely represents release of tau oligomers into the interstitial space following injury
caused by placement of microdialysis probe.

In order to show the utility of the assay we measured tau oligomers from media of two cell lines:
one expressing tau aggregates and one not. As shown in Table 2.7 below, amount of total tau was
similar between the two cell lines. However there is a big increase in the amount of tau
oligomers in the cell media of the cell line that expresses tau aggregates.

38

Calculated
Oligomer
Culture

Mean

media

AEB

20
20.11

oligomer

concentration concentration Total tau
SD

(pg/ml)

(pg/ml)

(ng/ml)

0.0448 0.00215 <8*

<40

13.89

0.0582 0.00756 48.91

244.55

16.19

Table 2.7. Successful detection of tau oligomers in cell media from cell lines.
Media was collected from two HEK293T cell lines, one expression RD tau aggregates, and one
without. The Simoa platform is able to detect and quantify tau oligomers.

2.3.6 Investigating the potential of a larger 3 megadalton probe in collecting
tau oligomers
All our microdialysis experiments thus far have used a 1 megadalton probe to collect tau. To
increase our probability of collecting higher order tau species we decided to test a 3 megadalton
microdialysis probe. In vitro microdialysis was performed as before. 1 ug/ml of monomer tau
was prepared and the probe was inserted into this solution. Fractions were collected in different
perfusion buffers (4% or 2% or 0.15% human albumin) at different flow rates (ranging from 0.5
ul/min – 2 ul/min).
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We noticed big changes in volumes of the stock solution from experiment to experiment, perhaps
indicating that instead of microdialysis these bigger probes are ultrafiltrating. We also noticed at
the lower flow rates the probe tends to get clogged. These inconsistencies make the 3 megadalton
probe not a very viable option for microdialysis.

Flow rate (ul/min)
0.5
0.8
1
1.5
2

Exp 1(4% albumin)
1.02
0.855
0.684
0.645
0.413

Conc of tau recovered (ng/ml) [initial=1 ug/ml]
Exp 2(4% albumin) Exp 3(2% albumin) Exp 4(2% albumin) Exp 5(2% albumin)
0.572
21.2
n/a
n/a
0.376
30.86
0.202
0.191
0.327
42.3
0.189
0.132
0.386
48.6
0.219
0.193
0.373
43.11
0.203
0.233

Exp 6(0.15% albumin)

Exp 7(0.15% albumin)

No recovery

Table 2.8.. Initial in vivo microdialysis experiments using a larger 3 megadalton probe.
Benchtop microdialysis was performed to assess zero-flow rate recovery of known amount of
tau, with varying concentrations of albumin. The probe was not successful in recovering tau
oligomers.

2.3.7 Assessment of seeding activity of various microdialysates
In addition to the ELISA we were looking for other methods to validate our collection of
oligomers by microdialysis. The FRET-based seeding assay using HEK 293T biosensor cells as
developed by the lab of Marc Diamond (Holmes et al. 2014) can detect presence of tau ‘seeds’ in
a given sample with high sensitivity. We tested seeding response to various microdialysates and
compared that to a FRET ‘standard curve’ generated using serially diluted sonicated full-length
fibrils. Results are shown in Figure 2.10. We were not able to detect seeding from WT fibrils
perhaps because they were not sonicated before adding to the biosensor line. However
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microdialysates from brain lysates and purified tau oligomers all show very robust seeding
response.

In vitro centimers

In vitro decamers

In vitro trimers

In vitro dimers

Centimers

Decamers

Trimers

Dimers

In Vitro P301S 9mo
male 2

In Vitro P301S 9mo
male 1

In vitro tau fibrils 2

800
700
600
500
400
300
200
100
0

In vitro tau fibrils 1

IFD fold change

FRET response of microdialysates

Samples

FRET standard curve with full-length fibrils
500

IFD fold change

400
300

200
100
0
0.0390625 0.078125

0.15625

0.3125

0.625

Concentration (ug/ml)
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1.25

2.5

5

Figure 2.10 Seeding response of various microdialysates as measured by the FRET-based tau
seeding assay.
Synthetic purified tau oligomers (i.e. dimers, trimers and higher-order species) gave a much
more robust FRET signal on the seeding assay than larger fibrils.

2.4 Discussion
Here we have systematically described the development and optimization of multiple tau
oligomer specific ELISAs: one specific for truncated RD tau oligomers and two for full-length
tau oligomers. Since microdialysis is a versatile technique allowing us to sample a broad range of
analytes from awake, freely moving animals, we naturally asked whether it could be adapted for
collection of putative tau oligomers. Before moving on to perform in vivo microdialysis in
animals we performed a series of benchtop in vitro experiments to demonstrate the viability of
the microdialysis in collecting tau oligomers. Our results show that we are able to recover a
small but measurable amount of oligomers from various input solutions. In addition we are able
to recover purified oligomers and oligomers from cell culture media. We confirmed the presence
of oligomers in the dialysate by performing the FRET-based tau seeding assay.
Separate from the optimization of microdialysis protocol, we used the oligomer-specific assay to
measure tau oligomers from brain lysates from different regions. We observed that a majority of
tau oligomers are present in the salt soluble fraction.
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Since putative tau oligomers are likely present in very small amounts in vivo in the interstitial
fluid we invested in the Simoa HD1 Analyzer, a single-molecule detection system. We
successfully translated our HJ 8.7/8.7b oligomer-specific assay to this new platform and noticed
a dramatic 80x increase in sensitivity.

Our initial attempts at measuring tau oligomers in ISF showed a slight increase in signal in one
animal. We are actively working on other methods of detecting tau oligomers. Recent
development of cerebral open flow microperfusion (cOFM) has opened the possibility of using it
to detect large tau species in ISF. Unlike microdialysis, which is inherently restricted by the
cutoff size of the membrane, OFM uses a micromesh that is open to the extracellular milieu
where the probe is implanted, and thus allows unrestricted access to molecules of all
sizes(Birngruber et al. 2013, Birngruber and Sinner 2016, Ghosh et al. 2014). In theory this
should allow for collection of oligomers.

In summary we have developed robust and sensitive tools that should enable us to characterize
and quantify tau oligomers from biological samples which should hopefully yield further insight
into the role of extracellular tau and its various species in pathogenesis of tauopathies.
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2.5 Methods
Preparation of fibrils
FL tau fibrils were prepared according to the protocol outlined in detail in previous work1,2.
10 µM FL tau was prepared and used in experiments. To induce fibrillization of tau monomer,
10 uM FL tau was incubated with 2mM for 45 min at room temperature. After that a solution of
10mM HEPES, 100mM NaCl, 8uM Heparin was added. This was incubated at 370 C for a week.

In vitro microdialysis
In vitro microdialysis was carried out (with some modifications) using the protocols outlined1,3.
In brief: Solution of FL tau fibrils (1 µg/ml) in 0.15% human albumin/PBS was used. For brain
lysates and purified oligomers, initial concentration was measured by HJ 8.7/8.7b ELISA before
and after microdialysis. A microdialysis probe with 3 megadalton pore size (MAB) was then
inserted in the different preps. Microdialysis samples were collected at various flow rates (0.5 –
2 ul/min). Fractions were collected and kept at 40 C but the experiment itself was conducted at
room temperature. After fraction collection, samples were loaded onto a half-well ELISA plate
(Costar) for the tau oligomer ELISA
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HJ 8.7/8.7b ELISA (FL tau oligomers)
Epitope: N-terminal region (117-122 aa)
Capture antibody: HJ 8.7 at 20 ug/ml in coating buffer
Detection antibody: HJ 8.7b at 0.1 ug/ml in 1% BSA/PBS
Blocking: 1 hour in 4% BSA/PBS at 370 C
Standard curve (generated using FL fibrils): 200 ng/ml to 1.15625 ng/ml
Simoa procotols
HJ 8.7=0.5 ug/ml
HJ 8.7b=0.8 ug/ml conjugated to 60x biotin
SBG=250pM
Standards=10 pg/ml – 10 ng/ml
Standard ELISA buffer (as described in the ELISA protocol references) was used as sample
diluent.
Pilocarpine treatment conditions
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20 minutes prior to seizure induction, mice were given scopolamine (1 mg/kg) i.p to block
peripheral effects of pilocarpine. Mice were given 250 mg/kg pilocarpine i.p to cause seizures
and cell death. Seizures were terminated 10 minutes later with pentobarbital given i.p.

Seeding assay
Seeding was performed following protocols and methods published in (Holmes et al. 2014)
Purified tau oligomers
These were obtained from the laboratory of Marc Diamond.
Sonication and size exclusion chromatography (SEC)- Labeled fibrils prepared in 3 separate
batches were sonicated using a Q700 Sonicator (QSonica) at a power of 100-110 watt
(Amplitude 65), each for different periods of time (60, 90, and 120 min). Samples were then
centrifuged at 10,000 x g for 10 min and 1 mL of supernatant was loaded into a HiPrep 16/60
Sephacryl S-500 HR column (GE Healthcare) and eluted in PBS buffer at 4°C. After measuring
the protein content of each fraction with a Micro BCA assay (Thermo Scientific) and
fluorescence using a plate reader (Tecan M1000), they were aliquoted and stored at -80°C until
use. Each aliquot was thawed immediately before use. The molecular weight of proteins in each
fraction was initially determined by running gel filtration standards (Bio-Rad) followed by FCS
analysis.
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Chapter 3 Dural lymphatics regulate clearance of
extracellular tau from the CNS
This chapter is adapted from a published journal article. The full citation is:

Patel, T. K., Habimana-Griffin, L., Gao, X., Xu, B., Achilefu, S., Alitalo, K., . . . Holtzman, D.
M. (2019). Dural lymphatics regulate clearance of extracellular tau from the CNS. Mol
Neurodegener, 14(1), 11. doi:10.1186/s13024-019-0312-x
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3.1 Abstract
Background
Alzheimer’s disease is characterized by two main neuropathological hallmarks: extracellular
plaques of amyloid-β (Aβ) protein and intracellular aggregates of tau protein. Although tau is
normally a soluble monomer that bind microtubules, in disease it forms insoluble,
hyperphosphorylated aggregates in the cell body. Aside from its role in AD, tau is also involved
in several other neurodegenerative disorders collectively called tauopathies, such as progressive
supranuclear palsy (PSP), corticobasal degeneration (CBD), some forms of frontotemporal
dementia, and argyrophilic grain disease (AGD). The prion hypothesis suggests that after an
initial trigger event, misfolded forms of tau are released into the extracellular space, where they
spread through different brain regions, enter cells, and seeding previously normal forms. Thus
understanding mechanisms regulating the clearance of extracellular tau from the CNS is
important. The discovery of a true lymphatic system in the dura and its potential role in
mediating Aβ pathology prompted us to investigate its role in regulating extracellular tau
clearance.
Methods
To study clearance of extracellular tau from the brain, we conjugated monomeric human tau with
a near-infrared dye cypate, and injected this labeled tau in the parenchyma of both wild-type and
K14-VEGFR3-Ig transgenic mice, which lack a functional CNS lymphatic system. Following
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injection we performed longitudinal imaging using fluorescence molecular tomography (FMT)
and quantified fluorescence to calculate clearance of tau from the brain. To complement this, we
also measured tau clearance to the periphery by measuring plasma tau in both groups of mice.
Results
Our results show that a significantly higher amount of tau is retained in the brains of K14VEGFR3-Ig vs. wild type mice at 48 and 72 hrs post-injection and its subsequent clearance to
the periphery is delayed. We found that clearance of reference tracer human serum albumin
(HSA) was also significantly delayed in the K14-VEGFR3-Ig mice.
Conclusions
The dural lymphatic system appears to play an important role in clearance of extracellular tau,
since tau clearance is impaired in the absence of functional lymphatics. Based on our baseline
characterization of extracellular tau clearance, future studies are warranted to look at the
interaction between tau pathology and efficiency of lymphatic function.
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3.2 Background
Alzheimer's disease (AD) is the leading cause of dementia in the elderly and currently affects
more than five million people in the United States. The two main neuropathological hallmarks of
AD are extracellular plaques of amyloid-β (Aβ) and intracellular accumulations of aggregated,
hyperphosphorylated forms of tau in structures such as neurofibrillary tangles (NFT) (Holtzman,
Mandelkow, and Selkoe 2012). The amyloid cascade hypothesis holds that the triggering event
in AD pathogenesis is the initial accumulation and aggregation of Aβ into oligomers and
insoluble extracellular plaques (Musiek and Holtzman 2015). This initiates a cascade that incites
the misfolding and aggregation of soluble tau into insoluble forms, eventually leading to
neurodegeneration. Loss of cognitive function in AD and other tauopathies is correlated with the
amount of aggregated tau accumulation. In addition to its key role in AD pathology, tau has also
been implicated in a host of other neurodegenerative disorders such as progressive supranuclear
palsy (PSP), corticobasal degeneration (CBD), certain forms of frontotemporal dementia (FTD)
and argyrophilic grain disease (AGD). Collectively termed tauopathies, these disorders all
feature aggregated forms of tau in the CNS (Mandelkow and Mandelkow 2012a, Li and Götz
2017).

One model explaining part of the pathogenesis of tauopathies is the prion hypothesis, which
states that misfolded forms of tau can exit the cell, spread to distant regions of the brain where
they can re-enter cells and “seed” previously normal forms of the protein, much like prion
50

protein (Jucker and Walker 2013, Davis, Leyns, and Holtzman 2018) Expression of mutant
human tau in neurons in the entorhinal cortex shows spread of tau pathology to synaptically
connected regions in the dentate gyrus of the hippocampus in mice (de Calignon et al. 2012, Liu
et al. 2012). In addition to seeding and uptake in cell culture (Holmes et al. 2014, Kfoury et al.
2012, Frost, Jacks, and Diamond 2009, Wu et al. 2013), injection of brain lysates from
transgenic mice (Ahmed et al. 2014, Clavaguera et al. 2014), cell lysates (Sanders et al. 2014),
synthetic recombinant tau fibrils (Iba et al. 2013, Peeraer et al. 2015) and tau extracts purified
from human brains (Clavaguera et al. 2013, Boluda et al. 2014, He et al. 2018, Lasagna-Reeves,
Castillo-Carranza, Sengupta, Guerrero-Munoz, et al. 2012, Guo et al. 2016)into mouse models
have also been shown to robustly induce uptake, seeding and spreading of tau pathology. If this
model of tau propagation is correct, it is likely that extracellular tau plays a key role in mediating
pathogenesis and progression of tauopathy. As a result understanding the mechanisms that
regulate tau fate in the extracellular space of the CNS and its eventual clearance to the periphery
is important.
Regulated clearance of substances out of the CNS to the periphery is vital to healthy functioning
of the CNS, and as such is an important and active area of research. For all the attention focused
on the brain in health and disease, little was known about fundamental clearance mechanisms
until relatively recently. For decades, it was thought the brain enjoyed a ‘true’ immune privileged
status because of an apparent lack of lymphatic drainage from the CNS. Early tracer injection
studies showed that peptides and solutes injected in the CSF and parenchyma eventually make
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their way to deep cervical lymph nodes (dCLNs) by traveling along olfactory sinuses and the
cribriform plates (Cserr, Harling-Berg, and Knopf 1992, Rennels et al. 1985).
More recent work, also largely done with tracers, refined this model further by proposing that
solutes are cleared across paravascular routes and are aided in this process by astrocytes. The
role of astrocytes in mediating this clearance led to this model being called the ‘glymphatic’ (a
portmanteau of glia and lymphatic) system (Xie et al. 2013). The water channel aquaporin 4
(AQP4), predominantly localized to astrocytic end-feet, was shown to be key to glymphatic
clearance, as its deletion impaired clearance of solutes to dCLNs (Iliff, Lee, et al. 2013, Iliff,
Wang, et al. 2013, Plog et al. 2015). This model proposes that the interstitial fluid (ISF)
compartment of the brain exchanges metabolites and macromolecules with the CSF
compartment. This is driven by arterial pulsation (Iliff, Wang, et al. 2013), which causes solutes
to exit the brain by following paravascular pathways aided by AQP4.
The characterization of this system has implications for aging and disease. Prolonged exposure to
Aβ aggregates has been shown to impair glymphatic function in mouse models (Peng et al.
2016). Deleting AQP4 leads to reduced transport of biomarkers of neuronal injury in a mouse
model of TBI (Plog et al. 2015) and exacerbates existing tau pathology, presumably because tau
aggregates are not cleared out of the brain properly (Iliff et al. 2014).
More recent work has upended accepted dogma by conclusively showing that the brain does
indeed have a ‘true’ lymphatic system responsible for draining macromolecules and cells from
the deep parenchyma. These studies demonstrated and rigorously characterized a network of
52

lymphatic vessels localized to the dura of the meninges using state of the art microscopy and
high resolution fluorescent imaging (Louveau et al. 2015, Aspelund et al. 2015). These dural
lymphatics were shown to track along superior sagittal and transverse sinuses, ultimately
draining into the deep cervical lymph nodes. Ablating dural lymphatics with either genetic
manipulation or surgery resulted in significantly slower clearance of injected macromolecules in
the deep parenchyma, perhaps indicating that the glymphatic and lymphatic system exist in
parallel and might even be linked (Aspelund et al. 2015, Louveau et al. 2017). Furthermore, it
was shown that impaired lymphatic drainage can exacerbate amyloid pathology, particularly in
the meninges (Da Mesquita et al. 2018).
Although it is known that extracellular clearance of Aβ is regulated by the transporters at the
BBB such as RAGE, LRP1, LDLR and P-GP (Deane et al. 2003, Castellano et al. 2012a, Shibata
et al. 2000, Elali and Rivest 2013, Tarasoff-Conway et al. 2015), by cellular enzymes such as
neprilysin (Iwata et al. 2001) and insulin-degrading enzyme (Qiu et al. 1998), and by glymphatic
flow (Iliff et al. 2012, Kress et al. 2014), data surrounding what regulates extracellular clearance
of tau is limited. Extracellular tau in various CNS compartments can be detected in the periphery
(Iliff et al. 2014, Yanamandra et al. 2017, Shahim et al. 2014), but it is unclear what regulates
this process. A recent study showed that various isoforms of tau are readily detected in plasma
following injection in the ventricles (Banks et al. 2016) but the mechanisms mediating this
process are unknown. There is also some evidence that the glymphatic system is involved (Iliff et
al. 2014); however, the role of the dural lymphatic system has not yet been studied. This lack of
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information and proper understanding of tau clearance prompted us to investigate the role of
dural lymphatic system in clearance of extracellular tau.

3.3 Results
3.3.1 Extracellular tau clearance is impaired and significantly more tau is
retained in the brain of K14-VEGFR3-Ig mice
We utilized the K14-VEGFR3-Ig transgenic mice for our studies. These mice lack a functional
dural lymphatic system (Aspelund et al. 2015)and thus provide a model to study the contribution
of this system to clearance of substances from the brain. We first confirmed that these mice lack
dural lymphatics by immunohistochemistry for LYVE1, a lymph endothelial cell marker (Figure
3.1). WT mice show clear distribution of lymphatic vessels along superior sagittal and transverse
sinuses, while K14-VEGFR3-Ig mice have no LYVE1 staining, indicating a complete lack of
lymphatic vessels.
To assess clearance of extracellular tau from the CNS over time, we performed serial FMT – an
optical imaging modality that allows for in vivo imaging of fluorescent probes through layers of
skin, bone and tissue – of mice injected with recombinant monomeric human tau labeled with
cypate, a near-infrared dye that can be easily conjugated to a number of different tracers, probes
and molecules for optical imaging of tumors and other physiological processes (Zhang et al.
2012, Achilefu et al. 2000, Ye et al. 2003, Ye et al. 2005). In this experiment, 4-6mo old WT and
K14-VEGFR3-Ig mice were imaged at 1, 2, 24, 48, 72 and 168 h post-injection of tau (Figure
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3.2a). Fluorescence was quantified in the brain to calculate amount of tau retained at each time
point. Signal for each mouse at each time point was normalized to the 1 h time point. As we
imaged mice over several days, we observed a clear result: tau clearance is delayed from the
brain in K14-VEGFR3-Ig mice. Significantly more tau is retained at 48 h (85% vs 52%) and 72 h
(52% vs 22%) post-injection in the K14-VEGFR3-Ig mice, strongly suggesting that in the
absence of dural lymphatics, extracellular tau is not as effectively cleared from the CNS to the
periphery (Figure 3.2b). This is reflected in the half-life of tau in both groups (Figure 3.2d): tau
has a shorter half-life of 39.67 h in WT mice compared to 154 h in the K14-VEGFR3-Ig mice.

3.3.2 Clearance of HSA from CNS is also impaired in K14-VEGFR3-Ig mice
To get a more clear understanding of tau clearance by lymphatics we repeated our experiment by
injecting HSA-cypate to serve as a reference tracer. Since it is known that albumin is cleared by
lymphatic vessels out of the CNS (Louveau et al. 2015, Aspelund et al. 2015), we hypothesized
delayed clearance of HSA in K14-VEGFR3-Ig mice. Longitudinal FMT of 4–6 mo WT and
K14-VEGFR3-Ig mice injected with HSA-cypate reveals that significantly more HSA is retained
in the brain of the transgenic mice at 24 h (57% vs 29%) and 48 h (36% vs 15%) compared to
WT mice (Figure 3.2c), suggesting that similar to tau, clearance of HSA is delayed in mice
lacking a functional dural lymphatic system. Additionally we found that half-life of HSA was
longer in K14-VEGFR3-Ig mice (26 h) compared to WT mice (~ 13 h). This is in agreement with
published reports of rat albumin’s half-life in rat brain (Cserr et al. 1981, Yamada et al.
1991)being in the range of 11–18 h, thus further validating this method to measuring CNS
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clearance of proteins. The fact that HSA is cleared faster than tau could perhaps indicate uptake
and/or additional extracellular retention of tau within CNS.

3.3.3 Measurement of plasma tau reveals a trend toward delayed clearance in
K14-VEGFR3-Ig mice
As we showed there is delayed clearance of extracellular tau from the brain, one would predict
that the amount of tau appearing in the blood would also be delayed. In order to study this
directly, we measured plasma tau in both groups of mice to complement FMT experiments
looking at brain retention of tau to get a more complete picture of tau clearance. We used an
antibody-mediated approach (Yanamandra et al. 2017) to increase half-life of soluble tau in the
plasma to allow us to measure it reliably. This was done because the half-life of tau once it
reaches the plasma is only 8.49 min; however, in the presence of the anti-tau antibody HJ8.5, the
half-life of plasma tau increases to 3.4 h allowing one to measure it there in a more facile fashion
(Yanamandra et al. 2017). Following intraperitoneal antibody administration of HJ 8.5 (an antihuman tau antibody), WT and K14-VEGFR3-Ig mice were injected in the hippocampus with
1.1 μg tau. Blood was collected at 2, 24, 48, 72 and 168 h post-injection and plasma human tau
was measured by a high-sensitivity ELISA on a Simoa analyzer. The plasma tau assay uses
capture antibody HJ8.7 (which binds to N-terminal epitopes 117–122 of tau) and biotinylated
detection antibody BT2 (which binds to epitopes 194–198 of tau). We found that K14-VEGFR3Ig mice, which retained a significantly higher amount of tau in the brain, correspondingly also
show delayed appearance of tau in the periphery (Figure 3.3) compared to WT mice. The amount
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of human tau in the plasma peaked earlier in the WT mice than in the K14-VEGFR3-Ig mice
(24 h vs. 48 h). Significantly higher plasma tau was present in K14-VEGFR3-Ig mice at 48 h,
when the WT mice had already cleared most of the tau from the periphery. Together with the
fluorescence data from the brain, these plasma tau measurements strongly suggest that impaired
dural lymphatic function leads to increased retention in the brain as well as delayed clearance of
tau to the periphery.

3.4 Discussion
While intracellular forms of tau are critical for its normal function as well as its role in
neurodegenerative diseases, extracellular forms of tau appear to have an important role in the
process of tau aggregate spreading transynaptically in different tauopathies as well as possibly in
a component of tau toxicity. Given this, it is important to understand what regulates the clearance
of extracellular tau from the brain. One important recently identified pathway that is involved in
extracellular protein clearance from the brain is the dural lymphatics. Because of the recent
discovery of bona fide lymph vessels in the meninges, we particularly focused on their role in
this process. By using the K14-VEGFR3-Ig mouse model, which lacks dural lymphatics and
shows delayed clearance of CNS macromolecules and tracers (Aspelund et al. 2015), we
demonstrated that extracellular tau clearance from the CNS is significantly impaired in the
absence of a functioning dural lymphatic system. A significantly higher amount of tau is retained
in the brain of the K14-VEGFR3-Ig mice and its eventual clearance and appearance in the
periphery is also delayed.
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As our work was done to establish ‘baseline’ clearance mechanism of monomeric tau, it opens
several exciting future directions: does disruption of lymphatic vessels exacerbate tau pathology?
What effect does age have on lymphatic clearance of tau? Is clearance of aggregated tau
markedly different than monomeric tau? The mice we used in our work are otherwise healthy
and do not show any neuropathological alterations (such as tau aggregation). As a result it would
be interesting to determine whether the clearance of tau is altered in the presence of significant
AD or other pathology as this will help us to understand if there is a link between CNS
lymphatics and neurodegeneration.
Since the glymphatic system appears to play a key role in the ISF-CSF exchange of solutes, we
can propose a model of extracellular tau clearance that traces the fate of ISF tau: following its
release into the ISF compartment, tau is cleared into the CSF space by the glymphatic system.
Once in the CSF it is drained to the cervical lymph nodes by the dural lymphatic system. Thus
the glymphatic and lymphatic systems most likely work in tandem to accomplish the eventual
clearance of tau to the periphery.
However one key observation from our FMT experiments in K14-VEGFR3-Ig mice is that
despite complete lack of lymphatic vessels, extracellular tau is still able to be cleared out of the
brain to the periphery, albeit at a much slower rate than in healthy WT mice. This implies the
existence of alternate paths for tau clearance and/or uptake within the CNS. Coupled with the
fact that passive clearance of HSA appears to be faster than passive clearance of tau (despite
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their similar molecular weights) this leads to the hypothesis that the dural lymphatic system
might show some specificity in transporting macromolecules out of the CNS. The potential
existence of alternate clearance mechanisms needs to be investigated further. K14-VEGFR3-Ig
mice lack a functional lymphatic system owing to lack of signaling through the VEGFR3
receptor. Mice show complete lack of lymph vasculature and profound lymphedema. They
survive the neonatal period despite these defects and subsequently even show regeneration of
lymph vasculature in the periphery. In adulthood they only lack the dural lymphatic system
(Aspelund et al. 2015, Mäkinen et al. 2001). Though these mice do not have any defects in
vascular permeability that are detectable, it is possible that abnormal development of peripheral
lymphatics might also lead to disturbance in degradation and eventual clearance of plasma tau.
Finally, in the process of investigating the contribution of dural lymphatics to extracellular
clearance we made extensive use of FMT, a technique that has previously been used mostly to
study tumor evolution and other related cellular processes in vivo (Zhang et al. 2012). We have
thus established a novel use for this versatile technique, which can hopefully be used for more
extensive clearance studies in the future.

3.5 Conclusions
We demonstrate a novel use of FMT in studying clearance of extracellular tau from the CNS.
Using a mouse model lacking functional lymphatics we performed longitudinal FMT to show
that tau clearance is notably impaired in the absence of functional lymphatics and its eventual
clearance to the periphery is significantly delayed, thus establishing a key role for the dural
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lymphatic system in mediating extracellular tau clearance. Our study highlights a likely link
between the glymphatic and lymphatic systems in mediating extracellular clearance and opens
new avenues to investigate the interplay between neurodegeneration and the dural lymphatic
system.

3.6 Methods
3.6.1 Animal surgeries and husbandry
Initial breeding pairs of K14-VEGFR3-Ig mice (Mäkinen et al. 2001) were obtained from Dr.
Kari Alitalo at the University of Helsinki and the colony was further expanded and maintained at
Washington University School of Medicine. The transgenic mice are crossed with C57/BL6
mice. WT and TG mice used in all the experiments were littermates.
WT and K14-VEGFR3-Ig mice were anesthetized with ketamine/xylazine cocktail before being
placed in the stereotactic surgery frame. Intrahippocampal injection of recombinant monomeric
human tau (labeled and un-labeled) and human serum albumin (HSA) was performed at the
following site: bregma − 2.5 mm, lateral 2 mm from midline, 2 mm ventral to the dura. All
procedures were performed following protocols approved by the Animal Studies Committee and
Washington University School of Medicine.
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3.6.2 Tau and HSA conjugation with cypate
Recombinant monomeric human tau (1N4R, tau-412, rPeptide) and HSA were conjugated with
near-infrared dye cypate in the following manner: Cypate conjugation to proteins was carried out
by NHS ester chemistry (Nanda and Lorsch 2014). Cypate-NHS was prepared by dissolving
31.3 mg (0.05 mmol) cypate in 200 μl DMSO. Next a solution of 5.8 mg (0.05 mmol) NHS, and
4.8 mg (0.025 mmol) EDC was prepared in another 200 μl DMSO solution. Finally the two
solutions were mixed and incubated overnight at room temperature. For conjugation, 100 μg tau
was reconstituted with 90 μl pH 7.4 1 X PBS buffer. Then 0.75 μl Cypate-NHS was diluted with
DMSO into 10 μl, and then added to the 90 μl tau solution and allowed to incubate for 2 h at
room temperature.
For HSA conjugation 1.0 mg HSA was dissolved in 200 μl pH 7.4 1 X PBS buffer. Next 1.5 μl,
Cypate-NHS DMSO solution was diluted with DMSO into 20 μl, added to the 200 μl HSA PBS
solution, and then incubated at room temperature for overnight. Reaction mixtures were dialyzed
with 1 X PBS, pH 7.4 at 4 °C for overnight, and then lyophilized. Dye and protein concentrations
were determined by protein assay (Bio-Rad) and UV-Vis absorption spectrum, to give dye to
protein molar ratio.

3.6.3 In vivo FMT of tau-cypate and HSA-cypate drainage
In vivo FMT was performed on a Perkin Elmer FMT4000 imaging system. Following intrahippocampal injection of cypate labeled tau, mice were anesthetized with 2% isoflurane for
imaging. Both WT and K14-VEGFR3-Ig mice were imaged at 1, 2, 24, 48, 72 and 168 h post61

injection of tau. A 2 μl of solution (1.1 μg) of monomeric human tau or HSA was injected at a
flow-rate of 0.2 μl/min. Fluorescence was quantified based on instrument calibration with cypate
phantoms. Total fluorescence of tau and HSA fluorescent conjugates was measured in manually
drawn ROIs approximating the brain and lymph nodes. To control for variability caused by
injection, data for each mouse at each time point were normalized to the fluorescent signal at the
1 h time point.

3.6.4 Plasma tau measurement
For plasma measurement, 50 mg/kg of anti-human antibody HJ 8.5 was injected intraperitoneally
as described in (Yanamandra et al. 2017). Mice were injected with 2 μl of solution (1.1 μg) of
unlabeled, monomeric tau 1 h post-antibody administration. Blood was collected at 2, 24, 48, 72,
168 h post-tau injection. Samples were spun at 8000 g for 10 min to obtain plasma. The Simoa
HD-1 analyzer (Quanterix Corp) was used to measure human tau in plasma as previously
described (Yanamandra et al. 2017).

3.6.5 Meningeal extraction and immunohistochemistry
Mice were anesthetized by intraperitoneal injection of pentobarbital (200 mg/kg) for perfusion
with ice-cold Dulbecco’s PBS with Heparin. Following perfusion, the skull cap was carefully
removed and fixed overnight in 4% paraformaldehyde. Intact meninges were then peeled off and
stored as floating sections in PBS until immunohistochemistry. For LYVE1 staining, meninges
were washed in PBS-Triton X-100 (0.5%) and blocked in PBS-T with 0.5% BSA at room
temperature. Sections were incubated with LYVE1-e660 (ThermoFisher) at 1:200 overnight at
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40 C. Sections were washed in PBS-T prior to mounting on slides in Prolong Gold antifade
reagent with DAPI (ThermoFisher) mounting medium. Slides were imaged on Zeiss Axio
Imager Z2 fluorescence microscope and Cytation 5 imaging reader (Biotek Imaging, Inc.).
Images were processed on ZEN software suite (Carl Zeiss, Inc.) and Cytation 5 imaging reader.

3.6.6 Statistics
Bulk of data plotting and statistical analysis were done on GraphPad Prism 5. For tau-cypate
(n = 6–9) and HSA-cypate (n = 4–6) injection and brain retention studies, a two-way ANOVA
with a Bonferroni post-test by was used to analyze the two groups of mice at each time point (i.e.
2, 24, 48, 72 and 168 h). For plasma tau measurement a mixed effects linear model was used to
compare plasma tau (pg/ml) for the two groups (WT n = 5, K14-VEGFR3-Ig n = 6) across five
times (2, 24, 48, 72, and 168 h). Akaike’s AIC was used to evaluate 15 ovariance structures to
determine the best fit model for the two analyses. Least square estimates of the differences
between groups (i.e., mouse types or drug treatment) at each time period were used to compare
the trajectory of response over time. All tests were conducted at the alpha = 0.05 level of
significance. All tests were run in PROC MIXED of SAS 9.4.
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3.7 Figures

Figure 3.1. Histological characterization of the dural lymphatic system.
Intact meninges from both WT and K14-VEGFR3-Ig mice were stained for cellular marker
DAPI (top) and the lymphatic endothelial marker LYVE1 (bottom). Representative sections are
shown here. WT mice show the characteristic distribution of dural lymph vessels along the
superior sagittal and transverse sinuses (as delineated by LYVE1 staining). K14-VEGFR3-Ig
mice have no LYVE1 staining.
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Figure 3.2. K14-VEGFR3-Ig mice retain significantly more tau in the brain following intra-CNS
injection.
A. Panel showing distribution and gradual clearance of tau-cypate (as measured by longitudinal
FMT) in a representative WT mouse from pre-injection through 168 hrs post-injection.
Monomeric recombinant human tau was conjugated with the near-infrared fluorescent dye
cypate and stereotactically injected in the hippocampus of WT and K14-VEGFR3-Ig mice. Mice
were longitudinally imaged with FMT at the time-points indicated. The same injection and
imaging timeline was followed for experiments involving clearance of HSA-cypate in WT and
K14-VEGFR3-Ig mice B. Significantly more tau is retained in the brain of K14-VEGFR3-Ig
65

mice, indicating delayed clearance. 4-6 mo old WT (n=9; 5 males, 4 females) and K14VEGFR3-Ig mice (n=6; 3 males, 3 females) were injected with tau-cypate in the hippocampus.
They were imaged with FMT at 1, 2, 24, 48, 72 and 168 hrs post injection. The amount of
fluorescence in the brain was quantified and normalized to values for the 1 hr time point. A
significantly higher amount of tau was retained in the K14-VEGFR3-Ig mice compared to WT
mice at 48hrs (85% vs 52% retention) and 72hrs (52% vs 22% retention), following injection.
Data was analyzed by a two-way ANOVA with a Bonferroni post-test. (** p-value <0.01). C.
Significantly more HSA is retained in the brain of K14-VEGFR3-Ig mice, indicating delayed
clearance. 4-6 mo old WT (n=4; 1 male, 3 females) and K14-VEGFR3-Ig mice (n=6; 4 males, 2
females) were injected with HSA-cypate in the hippocampus. They were imaged with FMT at 1,
2, 24, 48, 72 and 168 hrs post injection. The amount of fluorescence in the brain was quantified
and normalized to values for the 1 hr time point. A significantly higher amount of HSA was
retained in the K14-VEGFR3-Ig mice compared to WT mice at 24hrs (57% vs 29% retention)
and 48hrs (36% vs 15% retention) following injection. Data was analyzed by a two-way
ANOVA with a Bonferroni post-test. (** p-value <0.01, * p-value <0.05). D. Table summarizing
half-life of tau and HSA in the CNS following their injection in both WT and K14-VEGFR3-Ig
mice. The half-life of both proteins is longer in the K14-VEGFR3-Ig mice.
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Figure 3.3. K14-VEGFR3-Ig mice show delayed clearance of extracellular tau to the plasma after
intra CNS injection.
4-6mo old WT (n=6; 3 males, 3 females) and K14-VEGFR3-Ig mice (n=5; 3 males, 2 females)
were injected with anti-tau antibody HJ 8.5 to stabilize tau entering the plasma from the CNS to
allow for its measurement. An hour later recombinant monomeric human tau was injected in the
hippocampus and blood was collected at time points indicated. Plasma tau was measured using
the ultrasensitive Simoa HD1-Analyzer platform. Though the overall difference between tau for
the two mouse groups was not significant (p=0.6766), the interaction between the two mouse
groups over time was significant (p=0.0191). Plasma tau peaks earlier in WT mice compared to
K14-VEGFR3-Ig mice (24 vs 48 hrs). Amount of plasma tau is significantly higher in K14VEGFR3-Ig mice at 48 hrs compared to WT mice (p=0.0260), indicative of delayed clearance of
tau due to impaired lymphatics. Data was analyzed by mixed effects linear model. Akaike’s AIC
was used to evaluate 15 covariance structures to determine the best fit model for this analysis.
Least square estimates of the differences between the two mouse groups at each time period were
used to compare the trajectory of response over time.
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4.1 Abstract
Tauopathies are a group of disorders in which the cytosolic protein tau aggregates and
accumulates in cells within the brain, resulting in neurodegeneration. A promising treatment
being explored for tauopathies is passive immunization with anti-tau antibodies. We previously
found that administration of an anti-tau antibody to human tau transgenic mice increased the
concentration of plasma tau. We further explored the effects of administering an anti-tau
antibody on plasma tau. After peripheral administration of an anti-tau antibody to human patients
with tauopathy and to mice expressing human tau in the central nervous system, there was a
dose-dependent increase in plasma tau. In mouse plasma, we found that tau had a short half-life
of 8 min that increased to more than 3 hours after administration of anti-tau antibody. As tau
transgenic mice accumulated insoluble tau in the brain, brain soluble and interstitial fluid tau
decreased. Administration of anti-tau antibody to tau transgenic mice that had decreased brain
soluble tau and interstitial fluid tau resulted in an increase in plasma tau, but this increase was
less than that observed in tau transgenic mice without these brain changes. Tau transgenic mice
subjected to acute neuronal injury using 3-nitropropionic acid showed increased interstitial fluid
tau and plasma tau. These data suggest that peripheral administration of an anti-tau antibody
results in increased plasma tau, which correlates with the concentration of extracellular and
soluble tau in the brain.
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4.2 Introduction
Tauopathies including Alzheimer disease (AD), Down syndrome dementia, progressive
supranuclear palsy (PSP), corticobasal degeneration (CBD), Pick disease, certain forms of
frontotemporal lobar degeneration (FTLD), and chronic traumatic encephalopathy (CTE) are a
group of neurodegenerative disorders characterized by the hyperphosphorylation and aggregation
of the protein tau in the central nervous system (CNS) (Mandelkow and Mandelkow 2012b). Tau
is a cytosolic microtubule-associated protein that under normal conditions is localized primarily
in neuronal axons (Drechsel et al. 1992, Trinczek et al. 1995, Mandelkow and Mandelkow
2012b) . Its aggregation in specific brain regions in different tauopathies is directly associated
with neurodegeneration in those brain regions (Probst et al. 1988, Probst et al. 1996, Falcon et al.
2014, Saito et al. 2004) . Emerging evidence suggests that once tau aggregates in the specific
brain regions that are characteristic for each tauopathy, pathological forms of tau then spread
through synaptically connected neural networks (de Calignon et al. 2012, Liu et al. 2012).
As tauopathies are currently untreatable, a variety of approaches have been taken attempting to
target tau therapeutically. Despite the fact that tau is predominantly a cytosolic protein, it is
normally released into the extracellular space from neural cells and its release is regulated by
excitatory neuronal activity (Pooler et al. 2013, Yamada, Holth, Liao, Stewart, Mahan, Jiang,
Cirrito, Patel, Hochgrafe, et al. 2014). A number of studies in animal models have shown that
both active and passive immunization targeting tau can have beneficial effects on reducing tau
pathology and improving function (Yanamandra et al. 2013a, Asuni et al. 2007, Boutajangout et
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al. 2011, Castillo-Carranza, Sengupta, et al. 2014b, Chai et al. 2011b, Troquier et al. 2012,
Schroeder et al. 2016). One mechanism that may account for these effects is via the ability of
antibodies to block the intercellular spread of tau pathology. In recent studies, we found that a
mouse monoclonal anti-tau antibody, HJ8.5, was able to block the cellular seeding activity of
externally applied tau aggregates as well as decrease insoluble tau in the brain and improve
function (Yanamandra et al. 2013a). In exploring the potential mechanisms by which this antitau antibody might exert its effects, we found that peripheral administration of HJ8.5 to tau
transgenic mice that express human tau predominantly in the CNS, markedly increased plasma
tau (Yanamandra et al. 2015). This suggested that further exploration of the effects of anti-tau
antibodies and plasma tau might provide insight into tau metabolism in the CNS.
To further determine both the origin of plasma tau as well as the potential utility of plasma tau
measurements as a marker of CNS tau, we assessed plasma tau concentrations before and after
anti-tau antibody administration in a variety of mice expressing human tau as well as in human
subjects with PSP. Herein, we report that tau increased in the plasma of mice expressing human
tau as well as in the plasma of PSP patients following administration of an anti-tau antibody.
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4.3 Results
4.3.1 Anti-tau antibody dose-dependently increases plasma tau in transgenic
mice and human patients with tauopathy
We previously assessed the effects of administering the mouse monoclonal anti-tau antibody,
HJ8.5, to P301S Tau transgenic (Tg) mice that develop tau pathology in the brain beginning at
~5–6 months of age (Yoshiyama et al. 2007a). HJ8.5 is a high affinity antibody specific to
human tau that is directed to an epitope in the N-terminus amino acids 25–30 (Yanamandra et al.
2013a). In agreement with our previous report (Yanamandra et al. 2015), intraperitoneal (i.p.)
administration of HJ8.5 at doses ranging from 10–200 mg/kg to 3-month-old P301S Tau Tg mice
resulted in a large, dose-dependent increase in plasma tau 48 hours after antibody injection
(Figure 4.1A). Plasma tau in Tg mice was assessed using single molecule array (Simoa)
technology, a digital enzyme-linked immunosorbent assay (ELISA) detection system developed
by Quanterix Inc. (Rissin et al. 2010a, Rissin et al. 2011). Given that HJ8.5 has strong effects on
decreasing tau pathology and improving function when given chronically to P301S Tau Tg mice
over months, a humanized version of HJ8.5 was developed as a potential treatment for
tauopathies. It was administered to an individual with PSP as part of an expanded access
treatment protocol. Several doses of the humanized antibody were administered monthly. Tau in
human plasma was assessed using a plate-based human plasma tau ELISA (in contrast to the
Simoa technology) both prior to dosing administration and following a dose of 7.5 mg/kg given
intravenously. Consistent with peripheral administration of HJ8.5 to mice, intravenous
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administration of the humanized antibody to one PSP patient resulted in a robust increase in
plasma tau (Figure 4.1B). Baseline plasma tau in this individual was not detectable with the
human plasma tau assay used (lower limit of detection, 10 pg/ml) prior to antibody
administration. Following antibody administration, tau increased rapidly over 24 hours with
concentrations of tau reaching ~250 pg/ml over several days (Figure 4.1B). This is about 60-fold
higher than the amount of tau previously reported in human plasma by others (~4 pg/ml) using a
more sensitive assay (Zetterberg et al. 2013). To confirm this observation, we also measured
plasma tau in 3 additional participants receiving the same antibody in a phase 1 single dose study
in subjects with PSP. These 3 individuals received a single dose of 15 mg/kg and their plasma
tau was assessed (Figure 4.1C). As with the first individual administered the antibody, baseline
plasma tau was not detectable (< 10 pg/ml) with the human plasma tau assay utilized. However,
following antibody administration, plasma tau increased to ~150–300 pg/ml after 7–14 days.
Thus, consistent with our observations in Tg mice expressing human tau, plasma tau markedly
increased 50–100 fold over baseline at the doses used after peripheral administration of an antitau antibody to humans.

4.3.2 Antibody-mediated increase in plasma tau half-life enables tau detection
One possible mechanism by which tau antibodies could increase plasma tau is by altering the
half-life of tau once it enters the plasma. To test this hypothesis, we injected recombinant human
tau intravenously into the jugular vein of wild-type mice in the presence and absence of the antitau antibody HJ8.5 and assessed the clearance of tau from the plasma. Plasma tau was measured
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with the Simoa ELISA. We found that the half-life of intravenously injected human tau in
plasma was 8.49 minutes (Figure 4.2A, D). Administration of HJ8.5 (50 mg/kg, i.p.) one hour
prior to jugular vein injection of recombinant human tau extended the half-life of tau to ~3.4
hours (Figure 4.2B, D). We next co-incubated recombinant human tau with a 10-fold molar
excess of HJ8.5 and administered the tau-antibody complex intravenously to wild-type mice. Coincubation of HJ8.5 with tau increased the half-life of tau within the plasma to an even greater
extent ~13.2 hours (Figure 4.2C, D). These data suggested that the peripheral administration of
an anti-tau antibody increased plasma tau by binding to tau and extending the half-life of tau in
the plasma (Figure 4.2B, C, D).
To determine the extent to which tau in the extracellular space of the CNS enters the plasma and
is measurable in the plasma, we injected recombinant human tau into the cisterna magna of wildtype mice in the presence or absence of peripherally administered HJ8.5. In control mice, plasma
tau was detectable in the plasma within minutes after cisterna magna injection and exhibited a
half-life of 1.6 hours (Figure 4.2E, G). The increased half-life of CNS-injected tau versus
venous-injected tau likely reflected continued entry of tau from the CSF into plasma over several
hours following a single bolus injection. In HJ8.5-injected mice, human tau was detected in the
plasma within minutes after CNS injection, but the half-life was increased to almost 24 hours
(Figure 4.2F, G). This again suggested that the HJ8.5-tau antibody complex had a prolonged
half-life in plasma relative to tau alone, which likely accounted, at least in part, for the HJ8.5dependent increase in plasma tau.
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4.3.3 HJ8.5-induced increase in plasma tau occurs in different mouse models
expressing human tau
To further characterize the effects of HJ8.5 on plasma tau as well as to determine its origin, we
administered HJ8.5 at a dose of 50 mg/kg i.p. to a variety of human tau Tg mice. P301S Tau Tg
mice express human tau under the control of the prion promoter, which drives transgene
expression predominantly in the CNS, but also in peripheral tissues such as muscle. Therefore,
plasma tau is likely to be detectable under basal conditions in P301S Tau Tg mice due to some
expression of tau in peripheral tissues outside of the CNS (Figure 4.3A). We wanted to verify
that the increase in plasma tau in Tg mice following HJ8.5 administration was attributable to
CNS-derived tau. We administered HJ8.5 to two different mouse models, the hTau mouse, which
expresses human tau under control of the endogenous tau promoter, and in another mouse model
in which adeno-associated virus (AAV) 2/8-mediates expression of human tau with the neuronalspecific synapsin promoter in the brain (Andorfer, Kress, Espinoza, de Silva, et al. 2003). We
injected AAV type 2/8 expressing human P301S tau (AAV-syn-P301S) intracerebroventricularly
(ICV) into the brain of postnatal day 0 (P0) wild-type mice. This resulted in strong CNS
expression of human tau by 1-month of age, at levels comparable to those observed in 3 monthold P301S Tau Tg mice (Figure 4.3B). Unlike P301S Tau Tg mice, human tau was not detectable
in the plasma of either 2-month old hTau mice or 1-month old AAV-tau mice under basal
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conditions (Figure 4.3A). Plasma tau in different Tg mice was assessed using Simoa technology.
The lower limit of detection in the plasma tau Simoa assay we utilized in mice was ~1 pg/ml.
Injection with HJ8.5 increased plasma tau in hTau mice to 93 pg/ml and to ~20ng/mL for AAVtau mice (Figure 4.3A). Given the large difference between hTau and AAV-tau mice regarding
plasma tau detected following HJ8.5 administration, we decided to measure soluble human tau in
the mouse brain using a plate-based human tau-specific ELISA. We found that soluble tau was
much lower in hTau mice compared to P301S and AAV-tau mice (Figure 4.3C), suggesting that
the different plasma tau concentrations observed following HJ8.5 administration reflected
different concentrations of soluble tau within the CNS compartment. However, because of major
differences in the promoters used in these mice and both the amount and location of tau
expression between the human tau expressing mouse models, we decided to further test this idea
in just one model.

4.3.4 HJ8.5-induced increase in plasma tau is correlated with soluble brain
tau
Given that we saw differences in plasma tau elevation upon antibody injection that appeared to
be potentially related to differences in soluble tau in the brain, we hypothesized that we might be
able to detect pathology-dependent alterations in soluble tau using antibody-dependent
measurements in plasma tau. In previous studies, we characterized the amount of tau within the
interstitial fluid (ISF) as well as brain soluble and insoluble tau in P301S Tau Tg mice (Yamada
et al. 2011b). ISF tau represents tau present in the extracellular space of the brain that is released
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from neurons (Yamada, Holth, Liao, Stewart, Mahan, Jiang, Cirrito, Patel, Hochgräfe, et al.
2014). It is only a small fraction of the soluble brain tau assessed biochemically, which is
predominantly composed of cytosolic tau. In accordance with previous results, we observed an
age-dependent decline in soluble tau, an age-dependent increase in insoluble tau, and no agedependent change in the detergent-containing radioimmunoprecipitation assay (RIPA) buffer
solubilized tau (Figure 4.4A–C). Furthermore, we found higher ISF tau in young, presymptomatic P301S mice compared to aged 9-month-old P301S mice (Figure 4.4D). The amount
of ISF tau in 9-month-old mice was ~60% lower than in 3-month-old mice. No changes were
observed in total human tau expression by qPCR (Figure 4.4E).
Having established that aged mice bearing tau pathology exhibited decreased total soluble and
ISF tau, we next tested whether we would detect differences in antibody-dependent increases in
plasma tau between P301S mice of different ages before and after the onset of tau pathology.
After i.p. injection of HJ8.5 (50 mg/kg), plasma tau assessed with the Simoa assay increased
over 1–6 hours and remained elevated for more than a week compared to basal conditions in 3month, 6-month, and 9-month-old P301S mice (Figure 4.5A–C). As a control group, anti-human
Aβ antibody HJ3.4 at 50 mg/kg was injected into P301S Tau Tg mice. No change in plasma tau
was observed in these groups (Figure 4.5A–C). Interestingly, the amount of plasma tau in the
HJ8.5-injected mice was decreased by 60% in the 9-month-old mice during the first 24 hours
following HJ8.5 injection compared to the amount in the 3-month and 6-month-old groups
(Figure 4.5D, E). This result was in accordance with the observed decrease in total brain soluble
tau and ISF tau in 9-month-old compared to 3-month-old P301S mice (Figure 4.4A,D). To
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further investigate this relationship we plotted the amount of plasma tau in HJ8.5-treated mice as
a function of soluble brain tau and found a positive correlation between the amount of soluble
brain tau and plasma tau (Figure 4.5F). Together, these results suggest that brain extracellular tau
in ISF is in equilibrium with biochemically extractable salt-soluble pool of tau within the brain
and that the ISF pool of tau is able enter the plasma where it was captured and detected by an
anti-tau antibody.

4.3.5 Changes in mouse brain ISF and plasma tau detected by HJ8.5 after
neuronal injury
Whereas the data suggest that decreases in soluble brain tau and ISF tau that occur in 9-monthold versus 3-month-old P301S mice maybe reflected in plasma following HJ8.5 injection, we
wanted to determine whether injury-induced increases in extracellular tau could also be detected
in the blood following peripheral injection of the anti-tau antibody. We decided to assess the
effects of unilateral striatal infusion of a neuronal toxin, 3-nitropropionic acid (3-NP), on ISF
tau. Baseline striatal ISF tau was assessed in a group of P301S Tau Tg mice followed by infusion
of 3-NP through reverse microdialysis. This treatment resulted in a 10–20 fold increase in striatal
ISF tau over several hours (Figure 4.6A). We then stereotactically injected a group of P301S Tau
Tg mice bilaterally with either 3-NP or PBS into the striatum as described previously (Musiek et
al. 2016). Four hours later, mice received an i.p. injection of HJ8.5 (50 mg/kg). Plasma tau was
assessed prior to and after 3-NP or PBS injection using the Simoa tau assay. Plasma tau
increased in all mice administered HJ8.5 (Figure 4.6B). However, there was a significanty larger
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increase in plasma tau in mice given 3-NP compared to those given PBS (p<0.01) (Figure 4.6B).
This suggested that not only decreases but also increases in ISF tau could be detected in plasma
after treatment with an anti-tau antibody.

4.4 Discussion
Disease-modifying therapies including immunotherapies are emerging as potential treatments for
neurodegenerative diseases. Antibodies targeting Aβ are furthest along in this process (Spencer
and Masliah 2014); however, antibodies targeting tau and α-synuclein have also shown
promising results in animal models and have entered clinical trials (Valera, Spencer, and Masliah
2016, Pedersen and Sigurdsson 2015). A challenge moving forward in clinical trials for
neurodegenerative diseases characterized by protein aggregation is screening for patients that
have the aggregated form of the protein being targeted in the CNS, as well as determining
whether the therapy being utilized is hitting its target. In this study, we found that peripheral
administration of anti-tau antibody to mice expressing human tau as well as to humans with PSP
resulted in a marked increase in plasma tau. Our data indicated that the antibody-dependent
increase of plasma tau resulted primarily from CNS-derived tau and that plasma tau
concentrations appeared to reflect soluble, extracellular tau in the brain. The results of this study
in both humans and mouse models suggest a direct relationship between extracellular tau in the
CNS and plasma tau.
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Expression of tau is almost exclusively in neurons where it is present in the cytosol. It is also
released by neurons in the brain physiologically and can be detected in soluble forms in brain
ISF and CSF (Pooler et al. 2013, Yamada, Holth, Liao, Stewart, Mahan, Jiang, Cirrito, Patel,
Hochgrafe, et al. 2014). In brain ISF, tau has a long half-life, ~11 days in mice (Yamada et al.
2015). In human plasma, it is detectable in only low amounts ~4 pg/ml in humans (Zetterberg et
al. 2013). Our data suggest that when tau enters the plasma from the CNS, it is rapidly cleared
(Figure 4.2A). In the presence of a tau antibody, tau that enters the plasma binds to the antibody
and this extends the plasma half-life of detectable tau (Figure 4.2). It is also possible that some
antibody-tau complexes form initially in the CNS and then are cleared via the plasma with
normal clearance of antibody from the brain to the blood. Interestingly, our data suggest that the
amount of tau bound to anti-tau antibody in plasma is related to brain soluble tau and perhaps
more directly to extracellular tau such as that in the ISF. For example, after neuronal injury, ISF
tau and plasma tau both increased (Figure 4.6), possibly due to extracellular release of cytosolic
tau in the brain after injury. Also, we detected lower tau in the plasma of older P301S Tau Tg
mice with tau pathology following anti-tau antibody administration reflecting lower ISF tau and
brain soluble tau (Figure 4.5). While there was a difference in salt-containing reassembly buffer
(RAB) soluble tau in mice before versus after establishment of tau pathology between age
groups, there was no correlation between RAB soluble tau and plasma tau after administration of
anti-tau antibody within each age group. This may be similar to the observed relationship
between CSF Aβ42 and amyloid deposition in the brains of human patients with Alzheimer’s
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disease pathology and mouse models of amyloidosis in which once Aβ has aggregated then CSF
and ISF Aβ42 decreases (Fagan et al. 2006, Roh et al. 2012, Potter et al. 2013). However, low
CSF Aβ42 in individuals with amyloid deposition does not correlate with the absolute amount of
Aβ deposition within this group. Even though CSF Aβ42 does not correlate with the absolute
amount of amyloid deposition, it may be useful for clinical trial patient selection based on its
ability to discriminate between the presence or absence of amyloid deposition. Whether increases
in plasma tau following anti-tau antibody administration would be different in humans with a
primary tauopathy compared to healthy controls is currently not known but should be tested in
future studies.

We, and others, have found that administration of certain anti-Aβ antibodies results in a large
increase in plasma Aβ in both mice and humans that is predominantly derived from the brain
(DeMattos et al. 2001, DeMattos, Bales, Cummins, et al. 2002, Farlow et al. 2012, Asami-Odaka
et al. 2005, Winkler et al. 2010). The large increase in plasma Aβ seen with certain antibodies
may be due to a prolongation of plasma Aβ half-life when bound to antibody, perhaps similar to
what we report here with tau. Animal studies suggest that such changes in Aβ may also reflect
the amount of extracellular soluble Aβ in the CNS that is entering the blood (DeMattos, Bales,
Cummins, et al. 2002, Winkler et al. 2010). In fact, manipulations that alter brain to blood
clearance of Aβ, such as the brain expression of the low-density lipoprotein receptor, affect the
concentration of Aβ detectable in the blood following anti-Aβ antibody administration
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(Castellano et al. 2012b). There are, however, differences between extracellular CNS-derived Aβ
and tau. The half-life of ISF Aβ in mice is ~1.5–3 hours; the half-life of ISF tau in mice is ~ 11
days (Cirrito et al. 2003a, Yamada et al. 2015).

There are several limitations to this study. First, whether all anti-tau antibodies will increase
plasma tau as we report here is not yet known although others have also observed increases in
serum tau after administration of different anti-tau antibodies to human Tau Tg mice (CastilloCarranza, Sengupta, et al. 2014a, d'Abramo et al. 2016). Second, the differences in plasma tau
following anti-tau antibody administration that were observed in the presence or absence of tau
pathology or after neuronal injury in mice have only been studied in one mouse model, P301S
tau transgenic mice. Whether similar differences will be observed in other animal models of
tauopathy is not clear. Third, it is not yet known whether increases in plasma tau in PSP patients
that were observed following the administration of the anti-human tau antibody used herein will
reflect brain extracellular tau in humans. Given these limitations, as anti-tau antibodies have now
moved forward into clinical trials, it will be important to assess plasma tau across different
patient populations with both primary tauopathies such as PSP, corticobasal degeneration, Pick
disease, chronic-traumatic encephalopathy, and frontotemporal lobar degeneration (FTLD) with
MAPT mutations versus AD in which there is both Aβ and tau accumulation and changes in CSF
tau. Notably, whereas CSF tau is elevated in AD and following acute neuronal injury such as
stroke or traumatic brain injury compared to controls, CSF tau is not elevated in the primary
83

tauopathy PSP. In fact, CSF tau is lower in PSP patients than in age-matched controls (Arai et al.
1997, Wagshal et al. 2015, Perrin, Fagan, and Holtzman 2009).

A well-established observation is that there is an elevation of CSF tau in AD (Holtzman, Morris,
and Goate 2011). This is likely a completely different phenomenon than what takes place in
primary tauopathies. In AD, CSF tau is likely elevated due to neuronal and synaptic membrane
damage secondary to amyloid deposition, not directly due to tau aggregation. This was
demonstrated in a recent study where it was shown that murine CSF tau is normal in young
amyloid precursor protein (APP) Tg mice prior to amyloid deposition, but then progressively
increases once amyloid deposition begins to accumulate in the brain (Maia et al. 2013). Given
that these mice do not develop neurofibrillary tangles or tau aggregation, it suggests that
amyloid-linked neuronal/synaptic injury leads to an increase in ISF/CSF tau release independent
of tau aggregation. We report a similar phenomenon following acute brain injury in P301S Tau
Tg mice. In this mouse model of acute CNS neuronal injury following striatal 3-NP
administration, we found an increase in brain ISF tau, and also higher plasma tau following antitau antibody administration compared to mice given an anti-tau antibody with no neuronal
injury. Given these results, we would predict in patients with amyloid deposition and in
individuals with acute brain injury from stroke or head trauma that there would be an increase in
plasma tau compared to age-matched healthy controls following anti-tau antibody
administration.
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Given our findings, it will be important to determine whether differences in plasma tau following
anti-tau antibody administration can be utilized to screen for individuals with primary
tauopathies (where tau is the only major protein aggregating in the brain), for those with AD
(where both Aβ and tau are 2 major proteins aggregating in the brain), and for those with
different forms of acute versus chronic neuronal/synaptic damage. Finally, as clinical trials move
forward with anti-tau antibodies, it will be important to determine whether a reduction in tau
accumulation detected by tau imaging as well as any clinical response following anti-tau
antibody therapy correlates with measurements of plasma tau. In addition, understanding how
plasma and CSF tau correlate before and after anti-tau antibody administration may also provide
insights into the mechanism of action of anti-tau antibodies.

4.5 Materials and methods
4.5.1 Study design
The aim of this study was to assess concentrations of plasma tau in patients with PSP and in
mouse models expressing human tau before and after administration of an anti-tau antibody. In
mouse models, another goal was to determine the half-life of plasma tau in the presence and
absence of the anti-tau antibody as well as any differences in plasma tau after antibody
administration that were due to tau pathology. All mice and human subjects in the studies were
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randomly assigned to experimental groups. All studies were performed by investigators blinded
to treatment groups and sample identity. Replication numbers for experiments are listed in the
figure legends.

4.5.2 Administration of humanized HJ8.5 antibody to patients with PSP
The mouse monoclonal antibody was cloned from the hybridoma expressing HJ8.5 and the
variable regions were cloned to a human IgG4 Fc domain followed by humanization of several
amino acids outside of the CDR region. A humanized version of HJ8.5 was administered to an
individual with PSP following a treatment protocol under an expanded access program
(expanded access IND 119404) by C2N Diagnostics. Informed consent was obtained from the
individual and all procedures were approved by an Institutional Review Board. The individual
was administered multiple doses of the antibody once per month. Blood samples were collected
at various time points before and after start of drug infusion for the purpose of measuring drug
concentrations as well as biomarkers. The same antibody was also administered to individuals as
part of a phase I single dose study entitled “Safety, Tolerability, and Pharmacokinetics of C2N8E12 in subjects with Progressive Supranuclear Palsy”, NCT02494024. Informed consent was
obtained from all participants and all procedures were approved by an Institutional Review
Board.

4.5.3 Tau transgenic mice and treatment with anti-tau antibody
All animal procedure and experiments were performed by the guidelines approved by the animal
studies committee at Washington University School of Medicine. We utilized several different
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human Tau Tg mice. P301S Tau Tg mice (Jackson Laboratories) overexpress the human T34
isoform of human tau (1N4R) with the P301S mutation under the control of prion promoter (21).
These mice are on B6C3 background and develop tau pathology by 5–6 months of age. Human
tau (hTau) mice (male and female) were utilized that express all six isoforms of hTau but do not
express mouse tau (25). These mice develop hyperphosphorylated tau by 6 months of age (25).
For adeno-associated virus (AAV) injections, postnatal day (P) 0 pups of C57BL/6 mice were
used. Pregnant C57BL/6 mice were purchased from Charles River Labs. Plasma was collected
from two month-old hTau mice, 1-month-old AAV injected mice, and 3-month-old male P301S
Tau Tg mice one day before HJ8.5 injection and 48hrs after HJ8.5 (50 mg/kg) i.p. injection. For
dose response experiments, 3 month-old male P301S mice were administered HJ8.5 at 10, 50
and 200 mg/kg by i.p injection. Control mice were administered phosphate buffer saline (PBS).
All the plasma samples were stored at −80°C until use. For experiments involving P301S mice at
different ages (3-months, 6-months and 9-months), only male mice were utilized and plasma
samples were collected 1 day before HJ8.5 injection and at various time intervals (1, 6, 24, 72,
168 hours) after HJ8.5 (50 mg/kg) i.p injection. Anti-human Aβ antibody HJ3.4 was used as
control antibody. All plasma samples were stored at −80°C until use.

4.5.4 AAV viral particle injection into mouse brain
P301S human tau was cloned from P301S transgenic mouse cDNA and inserted into an AAVsynapsin driven promoter vector. AAV 2/8 serotype was produced at the Hope Center Viral
Vectors Core (Washington University in St. Louis). C57BL/6 mice post-natal day 0 (P0) pups
87

were intraventricularly injected bilaterally with 2 µl (1 × 1013 vg/mL) of AAV2/8 carrying
human tau with the P301S mutation (AAV-P301S) under the control of the synapsin promoter
using a 10 µl Hamilton syringe (Sigma-Aldrich). One month after viral infection, plasma was
collected from tail bleeds one day before injection and 48 hours after an i.p. injection of HJ8.5
(50 mg/kg). Plasma samples were stored at −80°C until use.

4.5.5 Collecting blood samples from mice
Blood samples were collected at various time points from tail bleeds for Tg mice and retroorbital bleeds for wild-type mice. Heparinized capillary tubes (Kimble & Chase) were used to
collect blood and transferred into 1.5 ml Eppendorf tubes along with 1 µl of 0.5M
Ethylenediamine tetraacetic acid (EDTA). The last time point of blood collection was from
anesthetized mice (50 mg/kg of sodium pentobarbital) from the right ventricle of the heart with a
1 ml insulin syringe filled with 20 µl of 0.5M EDTA. Blood samples were spun at 8000 rpm
(6000 × g) for 10 minutes at 4°C to obtain plasma. Plasma samples were stored at −80°C until
use.

4.5.6 Measurements of plasma tau half-life in mice
For experiments involving assessment of human tau half-life in the plasma of mice, recombinant
human tau (rPeptide), at 1 µg per 100 µl of saline, was injected into the jugular vein under
isoflurane anesthesia in 3 month old male B6C3 wild type mice, and retro-orbital bleeds were
collected at various time intervals (after 2, 4, 8, 12, 18, and 25 minutes). Recombinant human tau
(1 µg, rPeptide) was pre-incubated at room temperature with 10 times molar excess of HJ8.5 (2.3
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µM) and injected into the jugular vein of 3 month old B6C3 wild-type mice. Plasma was
collected from tail bleeds at different time intervals of 10 minutes, 6, 24, 48, and 72 hours. In
some experiments, 1 µg of recombinant human tau was injected into the jugular vein 1 hour
following the i.p. administration of HJ8.5 (50 mg/kg) and plasma was collected at 10 minutes, 1
hour, 6 hours, and 24 hours after injection. To determine the half-life of human tau in plasma
after administration into the cerebrospinal fluid in the cisterna magna, we anesthetized 3-month
old wild type male B6C3 mice by i.p injection of xylazine (10mg/kg)/ ketamine (100mg/kg) in
normal saline. Then mice were injected with recombinant human tau (2 µg/2 µl, rPeptide) into
the cisterna magna compartment as described previously (DeMattos, Bales, Parsadanian, et al.
2002). Plasma was collected from tail bleeds at different time intervals of 25 minutes, 1, 2, 3, and
6 hours. For experiments in the presence of HJ8.5 antibody, 10 minutes after i.p. injection of
HJ8.5 (50 mg/kg), human tau was injected into the cisterna magna. Plasma was collected at
various time intervals of 10 minutes, 1, 6, 24, 48, 72 hours. All Plasma samples were analyzed
on Simoa HD-1 analyzer. Half-life of tau was calculated by first order kinetics, determining
slope of linear regression from semi-log plot of concentration vs. time. Elimination rate constant
(Ke) and half-life t1/2 were calculated by using Ke= 2.0303/slope; t1/2=0.693/Ke as previously
described (Yamada, Holth, Liao, Stewart, Mahan, Jiang, Cirrito, Patel, Hochgrafe, et al. 2014,
Cirrito et al. 2003a, Castellano et al. 2011).

4.5.7 Immunohistochemistry to detect human tau
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Immunostaining was performed as described previously (Yanamandra et al. 2013a). To
determine the expression of human tau in different transgenic mice, we stained brain sections
with biotinylated HJ8.5 antibody. For staining, 3 brain sections of 50 µm thickness and 300 µm
apart corresponding approximately to sections at Bregma coordinates −1.4, −1.7, and −2.0 mm in
the mouse brain atlas were used (Franklin and Paxinos 1997). Brain sections were blocked with
3% milk in Tris-buffered saline and 0.25% (vol/vol) Triton-X followed by incubation at 4°C
overnight with the biotinylated HJ8.5 antibody. C57BL/6 and B6C3 wild type mice brain
sections were used as negative controls.

4.5.8 Measurements of plasma tau using the Simoa assay in mice
To measure tau in mouse plasma we utilized a Single molecule array – (Simoa) assay, a sensitive
digital ELISA platform (Wilson et al. 2016). Homebrew assays specific for total tau were
developed according to the manufacturer’s recommendations (Quanterix Corp). All plasma tau
levels measurements were analyzed using the Simoa HD-1 Analyzer (Quanterix Corp). Simoa
HD-1 consumables were purchased from Quanterix Corp. The paramagnetic beads were precoated with a mouse monoclonal anti-tau HJ8.7 capture antibody. In addition to the coated
beads, diluted plasma samples, biotinylated detector anti-tau antibody BT2 (Pierce), streptavidin
β-galactosidase (sβg), and enzyme substrate (resorufin β-D galactopyranoside) were added to the
Simoa HD-1 Analyzer. Recombinant human tau was included in each run to generate a standard
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curve. Assays were performed according to the manufacturer’s instructions (Quanterix Corp).
The presence of HJ8.5 in this assay does not interfere with or influence the assay results.

4.5.9 ELISA assay for plasma tau in PSP patients
To determine tau in human plasma samples, we utilized an ELISA in which plates were first
coated with 1 µg/mL of BT2 antibody (Thermo Scientific) in PBS supplemented with 20%
glycerol and left to incubate overnight at 4°C. The next day, plates were blocked with 2% BSA
in PBS supplemented with Tween-20 0.05% and 20% glycerol for 2 h at RT. Human plasma
samples were diluted 1:5 in sample diluent (0.20% BSA/300mM Tris PH 8.0/0.05% Tween
20/20 µg/mL mIgG/0.05% Proclin-300/PBS) while calibrator (recombinant tau 412, rPeptide)
was prepared in calibrator diluent (0.20% BSA/300mM Tris PH 8.0/0.05% tween-20/20 µg/mL
mIgG/20% pooled normal plasma samples/0.05% Proclin-300/PBS). Calibrators and samples
were incubated overnight at 4°C. The next day, plates were washed 4 times with PBS followed
by incubation with biotinylated mouse monoclonal anti-tau antibody HJ8.7 (1 µg/mL) in 1%
BSA in PBS for 2 h at RT. Plates were then washed 4 times with PBS followed by incubation
with streptavidin-poly-horseradish peroxidase-40 (1:6000, Fitzgerald) for 1 h at RT. Plates were
washed 4 times with PBS and then developed with Super Slow ELISA TMB (Sigma) and
absorbance read at 650 nm.

4.5.10 Biochemical extraction of mouse brain tissue
Biochemical extractions were performed as described previously (DeMattos, Bales, Parsadanian,
et al. 2002). Briefly, cortical brain samples were homogenized in 30 µl/mg (v/w) in reassembly
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buffer - RAB (100 mM MES, 0.5mM MgSO4, 1 mM EDTA, 2mM DTT, 0.75M NaCl, 1 mM
Na3VO4, pH 6.8) supplemented with 1× protease and phosphatase inhibitors (Roche). Samples
were spun at 50,000g for 20 minutes, and the supernatant was saved as a RAB-soluble fraction.
Pellet was dissolved in 30 µl/mg (v/w) in radioimmunoprecipitation assay (RIPA) buffer (150
mM NaCl, 50 mM Tris, 0.5% deoxycholic acid, 1% TritonX-100, 0.5% SDS, 25 mM EDTA, pH
8.0) supplemented with protease and phosphatase inhibitors (Roche) and spun at 50,000g for 20
minutes. The supernatant was collected as a RIPA-soluble fraction. The pellets were further
dissolved in 70% formic acid (FA) at 10 µl/mg, sonicated, centrifuged at 50,000g for 20 minutes.
The supernatant was collected as FA-soluble fractions. All fractions were stored at −80°C until
analyzed. Samples were analyzed using a human tau specific ELISA.

4.5.11 Human tau specific ELISA to measure tau in mouse brain
Human tau specific enzyme-linked immunosorbent assay (ELISA) that was utilized to measure
brain tissue tau levels was performed as described previously (Yanamandra et al. 2015). For
assessing human tau levels in Figure 4, biochemical cortical brain extraction samples were
analyzed by coating ELISA 96 well plates with mouse monoclonal anti-tau antibody Tau5 (20
µg/ml, gift of L. Binder) overnight. Plates were washed 5 times with PBS and blocked with 4%
BSA in PBS for 1 hr at 37°C. Cortical brain extraction samples were diluted in 0.25% BSA in
BSA, 300 mM Tris, pH 8.0 supplemented with protease inhibitors and kept at 4°C for overnight
on a shaker. The next day, plates were washed 8 times with PBS followed by the addition of
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mouse monoclonal anti-human tau-specific biotinylated HT7 antibody (0.2 µg/ml, Thermo
Scientific) in 1% BSA in PBS for 1.5 hr at 37°C. Next, plates were washed 8 times with PBS
followed by addition of streptavidin-poly-horseradish peroxidase-40 (1:6000, Fitzgerald) for 1.5
h in the dark at room temperature. Then plates were washed 8 times with PBS, developed with
Super Slow ELISA TMB (Sigma) and absorbance read at 650 nm. For assessing human tau
levels as shown in Figure 3C, cortical brain extracts of different transgenic mice were analyzed
by coating ELISA plates with anti-tau antibody BT2 (1 µg/ml) in PBS supplemented with 20%
glycerol and incubated overnight at 4°C. Plates were blocked with 2% BSA in PBS
supplemented with Tween-20 0.05% and 20% glycerol for 2 h at RT. Next plates were washed 4
times with PBS followed by the addition of mouse (Yamada et al. 2011a, Yamada, Holth, Liao,
Stewart, Mahan, Jiang, Cirrito, Patel, Hochgrafe, et al. 2014)monoclonal anti-human tau-specific
biotinylated HT7 antibody (0.2 µg/ml, Thermo Scientific) in 1% BSA in PBS for 1.5 h at 37°C.
Then plates were washed 4 times with PBS followed by incubation with streptavidin-polyhorseradish peroxidase-40 (1:6000 Fitzgerald) for 1 h at RT. Plates were washed 4 times with
PBS and then developed with Super Slow ELISA TMB (Sigma) and absorbance read at 650 nm.

4.5.12 Quantitative PCR to measure human MAPT RNA in mouse brain
tissue
For the isolation of RNA, brain tissues were homogenized in TRIzol (Invitrogen). Chloroform
was added (1:5 ratio), samples were vigorously shaken for 15 seconds at room temperature, and
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then centrifuged at 12,000 × g for 15 minutes at 4°C. The aqueous phase of the sample was
removed by angling the tube at 45° and pipetting the solution out. Then samples were diluted
(1:1) in 100% isopropanol and incubated for 10 minutes at room temperature. Samples were
centrifuged at 12,000 × g for 10 minutes at 4°C. The pellet was washed in 75% ethanol, and then
centrifuged at 7500 × g for 10 minutes. Supernatant was discarded and the RNA pellet air-dried
for 10 minutes before resuspension in RNase-free water. Reverse transcription was performed by
using a high-capacity RNA-cDNA kit (Applied Biosystems (ABI)). Quantitative PCR was
performed using an ABI TaqMan primer targeting human MAPT (Product no: Hs00902194_m1,
Life Technologies) and reagents on an ABI Prizm 7500 thermocycler according to the
manufacturer’s instructions. All mRNA measurements were normalized to the total cDNA

4.5.13 Microdialysis and 3-NP treatment of P301S Tau Tg mice
P301S hippocampal microdialysis was performed in P301S male mice with some modifications
(Yamada et al. 2011a, Yamada, Holth, Liao, Stewart, Mahan, Jiang, Cirrito, Patel, Hochgrafe, et
al. 2014). In brief, a microdialysis probe with 100 kDa cutoff (Amuza Inc.) was implanted in the
left hippocampus through a guide cannula (Amuza Inc.). Artificial cerebral spinal fluid (ACSF)
containing 4% human albumin solution was used as perfusion buffer for ISF collection. ISF was
collected in 90-minute fractions for 24 hours following probe implantation. Striatal microdialysis
with 3-nitropropionic acid (3-NP) treatment was performed in 8–9-month-old P301S mice using
a microdialysis probe with 1000 kDa cutoff (Amuza Inc.) implanted in the left striatum. ACSF
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containing 4% human albumin solution was used as perfusion buffer for ISF collection. After
stable baseline ISF collection 200 µM 3-NP (Sigma-Aldrich) was dissolved in perfusion buffer
and administered directly in the striatum for 3 hours via reverse microdialysis. For bilateral
striatal 3-NP injections combined with plasma tau measurements, a 100 nmol/µl solution of 3NP (Sigma-Aldrich) was prepared in PBS and 0.5 µl of this solution was injected bilaterally in
the striatum of 5 month old P301S mice via stereotaxic surgery at Bregma coordinates − +0.98
mm, +/− 1.5 mm mediolateral, and a depth of 2.6 mm as described (Musiek et al. 2016).

4.5.14 Statistical analysis
The amount of plasma tau in P301S mice of different ages was compared by 2-way ANOVA
with post hoc Dunnett test using GraphPad Prism 6.0 (GraphPad Software Inc.). Non-parametric
Spearman correlation analyses were performed with Graph Pad Prism 6.0 software. The Area
Under the Curve (AUC) for tau in plasma during the 24 hours following injection of anti-tau
antibody was calculated using the basic non-comparmental pharmacokinetics (PK) package for
R. R is a free software environment for statistical computing and graphics. The mean AUCs and
error estimates for each group were calculated by PK and a 2-tailed t-test was used to determine
statistical significance. One-way ANOVA followed by post-hoc Dunnett’s test was used to
evaluate the qPCR data, plasma tau-half life data, as well as ISF human tau. 2-way ANOVA with
post hoc Dunnett test was used to evaluate plasma tau measurements from mice administered the
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neurotoxin 3-NP. Statistical significance was set at p<0.05. Outliers were determined by
performing Grubbs’ test using free web Graph Pad software. There was one outlier each in the 6
and 9 month old groups of mice analyzed in Figure 4 and and55 for plasma and brain tau. All
values are presented as mean ± SEM.

4.6 Figures

Figure 4.1. Dose dependent increase in plasma tau after anti-tau antibody administration in mice
and humans.
(A) 3 month-old P301S Tau Tg mice were administered phosphate-buffered saline (PBS) or antitau antibody HJ8.5 at 10, 50 and 200 mg/kg doses (n=5 mice/group) by i.p injection. Plasma tau
was measured before the injection (pre-bleed) and 48 hours after antibody injection. Plasma tau
level measurements were analyzed using the Simoa HD-1 Analyzer. **p≤0.01, ****p≤0.0001,
one-way ANOVA followed by Dunnett’s post-hoc test for multiple comparisons. (B) Humanized
HJ8.5 at a dose of 7.5 mg/kg was intravenously injected into a single individual and plasma tau
was measured before (0 hour time) and after antibody injection at various time intervals (1, 2, 4,
5, 14, 28 days). (C) Humanized HJ8.5 at a dose of 15 mg/kg was intravenously injected into
three human subjects and plasma tau was measured before and after antibody injection. Tau was
not detected with this assay prior to antibody injection. Human plasma samples were analyzed
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with a human plasma tau ELISA assay. N=3 for each time point shown. Values represent mean
± SEM.

Figure 4.2. Half-life of plasma tau in absence and presence of anti-tau antibody.
(A) Human tau was injected intravenously (i.v.) into wild-type (WT) B6C3 mice (n=6) and
plasma tau was analyzed at 2, 4, 8, 12, 18 and 25 minutes (min). (B) Human tau was injected i.v.
into WT B6C3 mice (n=9) 1 hour following i.p. administration of HJ8.5 at 50 mg/kg and plasma
tau was analyzed after 30 minutes, 6 hours, and 24 hours. (C) Human tau was pre-incubated 1
hour with 10x molar excess HJ8.5 and injected into the jugular vein of WT mice (n=8). Plasma
was collected at 10 minutes, 6, 24, 48, and 72 hours. (D) Half-life of plasma tau following
97

jugular vein injection of tau in the conditions studied in A, B, and C. (E) Human tau was injected
into cisterna magna of WT B6C3 mice (n=6) and plasma collected at 25 minutes, 1, 2, 3, and 6
hours. (F) Ten minutes after HJ8.5 injection (50 mg/kg, i.p.), human tau was injected into the
cisterna magna of WT mice (n=6) and plasma collected at 10 minutes, 1, 6, 24, 48, 72 hours. (G)
Half-life of plasma tau after injection into cisterna magna in the absence (E) and presence of
HJ8.5 (F). Tau half-life was calculated by determining the slope from linear regression fit of
semi-log plots of concentration vs. time (Cirrito et al. 2003a). Values in D and G represent mean
± SEM. *p≤0.05, **p≤0.01, ***p<0.001. Values in D analyzed by ANOVA followed by posthoc Dunnett’s test and values in G analyzed by unpaired t test.

Figure 4.3. Increase in plasma tau after HJ8.5 injection in different models expressing human tau.
(A) Plasma tau was analyzed before antibody injection (pre-bleed) and 48 hours after HJ8.5
injection in 2 month-old hTau mice (n=5), 3 month-old P301S mice (n=8) and 1 month old
AAV-Syn-P301S (n=8, labeled as AAV). (B) Representative coronal brain sections of 1 monthold mouse with AAV2/8 mediated expression of P301S human tau under control of synapsin
promoter (AAV-Syn-P301S), 3 month-old P301S Tau transgenic mouse (P301S), and a 1 monthold C57BL/6 wild type (WT) mouse stained with biotinylated anti-human tau antibody HJ8.5.
Scale bars 600 µm in length. (C) Human tau levels measured by human tau specific ELISA in
brain cortical RAB-soluble fractions of 2-month-old hTau mice, 3-month-old P301S mice and 1
month-old AAV-Syn-P301S mice (AAV). Values in A and C represent mean ± SEM.
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Figure 4.4. Soluble brain tau and ISF tau decrease and insoluble tau increases with the presence of
tauopathy in P301S Tau Tg mice.
Levels of brain cortical RAB soluble (A), RIPA soluble (B) and 70% FA soluble tau (C) are
shown in 3-month (n=10), 6-month (n=15) and 9-month (n=14) old P301S Tau Tg mice. Nine
month-old P301S mice have significantly lower cortical RAB soluble and higher formic acid
soluble tau compared to 3- or 6-month old P301S mice. One-way ANOVA followed by post-hoc
Dunnett’s test, **p≤0.01, ****p≤0.0001. (D) Soluble ISF human tau was measured by
microdialysis in hippocampi of 3 month old (n=9) and 9 month old (n=7) P301S mice that were
not treated with an anti-tau antibody. Nine month old mice have significantly lower ISF tau
compared to 3 month old mice. *p≤0.05, 2-tailed t-test. (E) Levels of human tau mRNA in
cortex from 3- (n=10), 6- (n=14) and 9-month (n=9) old P301S Tau Tg mice. Tau mRNA levels
were normalized to total cDNA levels. 6 and 9 month-old P301S mice mRNA levels were
normalized and compared to 3-month old P301S mice. No difference in human tau mRNA levels
between groups were observed (one-way ANOVA post-hoc Dunnett’s test, p>0.05). Values
represent mean ± SEM.
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Figure 4.5. Anti-tau antibody mediated increase in plasma tau is significantly lower in 9 month old
P301S Tau Tg mice and correlates with levels of soluble brain tau.
Plasma tau was measured before (0 hour time point) and following i.p injection of HJ8.5 (50
mg/kg) or anti-human Aβ antibody HJ3.4 (50 mg/kg) at 1, 6, 24, 72 and 168 hours in 3 (A), 6 (B)
and 9 month (C) old P301S Tau Tg mice (n=10-15 mice/group). (D) Plasma tau levels measured
in 3 (black bars), 6 (gray bars) and 9 month (red bars)-old P301S mice, before (0 hour time
point) and after HJ8.5 i.p injection are presented in the bar graph. *p≤0.05, **p≤0.01, 2-way
ANOVA with post hoc Dunnett test. (E) Area under the curve (AUC) of plasma tau (pg/ml x
hours) was calculated for the first 24 hours after HJ8.5 injection in 3, 6 and 9 month old P301S
mice. *p=0.04, **p=0.004, 2-tailed t-test. Values represent mean ± SEM. All plasma samples
were analyzed on a Simoa HD-1 Analyzer. (F) Positive correlation is seen between plasma tau
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levels over 24 hours after HJ8.5 injection (y-axis) and brain cortical RAB soluble tau (x-axis).
Spearman r, r=0.51, ***p=0.0007. Blue squares, 3 month old mice, Red squares, 6 month old
mice, Black squares, 9 month old mice.

Figure 4.6. Injury to the striatum following administration of the mitochondrial toxin 3nitropropionic acid (3-NP) leads to increase in human tau levels in the ISF as well as plasma
following anti-tau antibody administration.
(A) Soluble ISF human tau was measured by microdialysis in the striatum of 8-9 month old
P301S Tau Tg mice (n=4). After stable baseline collection, 3-NP was administered via reverse
microdialysis for 3 hours and levels of tau were measured. Injuring the striatum causes
significant elevation in ISF tau for 12 hours post 3-NP treatment. One-way ANOVA followed by
post-hoc Dunnett’s test p<0.05. (B) Four to five month old P301S mice were injected bilaterally
in the striatum with either PBS (n=5) or 3NP (n=5, 100 nmol/µl). Four hours later, HJ8.5 at 50
mg/kg was i.p administered and plasma tau was assessed before (0 hour) and after 3-NP or PBS
injection at 24, 48 and 72 hours. Compared to PBS treated animals, there was significant
elevation of plasma tau in animals injured by 3NP treatment at 48 and 72 hours (2-way ANOVA
with post-hoc Dunnett test, **p<0.01, *p=0.029).
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Figure 4.7. Model of plasma tau clearance in the presence and absence of anti-tau antibody.
(A) Tau is released into the ISF by neurons under healthy/physiological conditions. Some
extracellular tau in the ISF and CSF reaches the blood where it is rapidly cleared. Green circles
represent soluble, monomeric tau and green cell represents neurons under healthy conditions. (B)
After peripheral administration of anti-tau antibody, tau exits the CNS where it binds to an antitau antibody (orange – Y shaped structures). Anti-tau antibody binding of tau extends the half–
life of tau in plasma by slowing its clearance rate. Antibody-tau complexes can form either in
plasma after tau exits the CNS or potentially within the CNS prior to efflux to plasma. (C) In
pathological conditions such as in a primary tauopathy, tau becomes hyperphosphorylated and
aggregates in neurofibrillary tangles and dystrophic neurites (clump of green circles). Under
these conditions, levels of soluble ISF tau are decreased and insoluble tau is increased. After
administration of an anti-tau antibody, less soluble, extracellular tau exits the CNS. The anti-tau
antibody still slows plasma tau clearance but lower plasma tau levels are now detected than in
healthy conditions because less extracellular tau is exiting the CNS. Red neuron represents
neurons under pathological conditions.
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Chapter 5 Discussion and future directions
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5.1 Golden age of tau
A simple pubmed search for keywords ‘tau’ and ‘Alzheimer’ returns about 11000 search results.
When the results are graphed by year a striking trend emerges: a near-exponential growth in the
number of publications in the last 35 years. While 1984 just had 1 publication –
“Immunoglobulin and other proteins in the cerebrospinal fluid of patients with Alzheimer's
disease” (Chapel, Esiri, and Wilcock 1984) – 2017 saw an astonishing 1075, more than 3
publications a day. What has driven this intense interest in a once obscure cytosolic protein with
an unglamorous binding role?
One big reason is the frustrating lack of disease modifying therapies in AD. Advances in medical
science have certainly extended lifespan considerably. As the population ages, the incidence of
dementia and neurodegenerative diseases (which, barring the small fraction of familial cases
caused by Mendelian mutations, are quintessentially disorders of old age) rises. As a result nearHerculean efforts have been made to decipher the pathogenesis of neurodegeneration (and in
particular, AD) in hopes to finding a cure. Setbacks suffered during multiple passive
immunotherapies against abeta caused a gradual but firm shift towards finding alternative
targets. Tau is an attractive target because of its involvement in many different
neurodegenerative conditions. So after relative stagnancy for two decades, the field of tau study
has seen a resurgence.
Another factor contributing to this rise in interest is the development and evolution of cuttingedge techniques in imaging, genetics, genomics and molecular biology. Advances in imaging
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modalities have led to development and clinical trials of imaging tracers designed for early
detection. We are now able to resolve various structural conformations of tau by high-resolution
microscopy. Transgenic mouse lines have made modeling tauopathy a straightforward affair as
these mice faithfully reproduce human tangle pathology. Mouse lines with regulatable tau
expression provided the first in vivo evidence of trans-synaptic propagation. Human iPSCs have
revolutionized the study of disease. They can be used to screen for drugs and model disease
processes in a rapid manner. By mining massive datasets genomics researchers have been able to
uncover novel mutations, rare variants and other disease related SNPs that have all spurred even
more research. Breakthroughs in single-cell sequencing have made it possible to get a granular
view of cell-type and brain region specific expression of not just tau but related genes, providing
a better understanding of cellular interactions in disease.
In pathogenesis, one of the biggest unanswered questions about is the identity of tau species
mediating prion-like spread of tau pathology. In diagnostics, it is the development of reliable
imaging agents to aid in early detection of tau pathology. In therapy, it is the effectiveness of
passive immunotherapy. The confluence of factors discussed above has made it very likely that
we will have answers to these pertinent questions in the coming years. Early diagnosis is
absolutely essential for therapeutic interventions and as such, biomarker efforts carry great
importance, possibly more than ever.
Here is a brief summary of progress made in plasma biomarkers (particularly tau) by others in
the field:
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5.1.1 Tau as a biomarker
Impressive progress has been made in using plasma tau levels as biomarker for diagnosis,
disease staging, and potential therapeutic monitoring. Currently approved diagnostics for AD
include a PET scan for amyloid plaques as well as a CSF biomarker panel that, among other
things, quantifies CSF total tau, phospho-tau (ptau), and the ratio of two amyloid-beta species.
CSF studies are by nature invasive and are difficult to use for longitudinal studies.
Unsurprisingly, recent efforts have focused on finding and validating a plasma biomarker(H et
al. 2017, CC et al. 2018).
One study comparing healthy controls, mild cognitive impairment (MCI) and AD patients found
higher levels of total tau and ptau181 in AD patients. Additionally, there was a positive
correlation between ptau181 levels and tau tangle and amyloid plaque load in the brain, as
measured by PET (Mielke et al. 2018).
Could this be used for other tauopathies? This question was addressed recently by a slew of
studies looking at two different ptau species: ptau181 and ptau217. In addition to recapitulating
earlier studies, this new work demonstrated that ptau181 can differentiate between different
stages of disease pathology in AD. Cognitively normal or mildly impaired patients with high
plasma ptau181 were more likely to develop AD in this analysis. Plasma ptau181 was also
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shown to be able to differentiate between AD and other tauopathies(Shorena, Mattsson, et al.
2020).
Two other studies performed similar analyses with ptau217 and found that it performed even
better than ptau181 at predicting progression to AD dementia as well as distinguishing AD from
other tauopathies. A striking feature of these studies is while one of them studies plasma ptau217
with an ELISA(Shorena, Stomrud, et al. 2020), the other studied CSF ptau217 using advanced
mass spectrometry techniques(NR et al. 2020), lending credence to the putative status of ptau217
as a superior biomarker.
As always, more work will be needed to validate the clinical applicability of these biomarkers
but the fact that plasma levels of these ptau species appear to correlate well with pathology load
as measured by multiple different modalities i.e. PET, CSF ELISA indicates high value in this
approach.

5.2 Quo vadis?
The work presented here aimed to make a small contribution to understanding tau’s role in
neurodegeneration. Although we were not able to find evidence of tau oligomers in vivo in ISF,
our development of high-sensitivity assay as well as preliminary in vitro results will hopefully
serve as a scaffold for future work in this direction.
Our work on extracellular tau clearance strongly suggests that dural lymphatics play a major
role. One notable study refined the anatomical location and distribution of dural lymphatic
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veseels, showed that a subsection of these vessels is probably responsible for draining a majority
of CSF macromolecules, and that this network is negatively affected in aging (JH et al. 2019).
Finally our published work identifying correlation between plasma tau and CNS soluble tau has
important implication for design of therapeutics and for monitoring disease progression. Our
approach of using an antibody to increase plasma half-life of tau in tauopathy can be used to
study tau levels in other models as well. As mentioned above further work doing direct
measurement of plasma tau levels (Shorena, Mattsson, et al. 2020, Shorena, Stomrud, et al. 2020,
NR et al. 2020) has shown great promise to be an effective biomarker not just for AD but for
other tauopathies.
The life of tau, this seemingly prosaic axonal protein with no definitively established function, is
complicated and multi-faceted, and as we unravel more of its life story we are bound to get
closer to solving neurodegeneration.
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